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ABSTRACT 
Oxidative stress is commonly associated with diet-induced metabolic 
syndrome (MetS) and left ventricular cardiac remodeling, but much remains 
unknown about the role of redox signaling, sensors, and switches in mediating the 
effects of high fat and sugar intake. In this work, I describe and apply an optimized 
method for quantifying changes in reversible protein-cysteine oxidation in the 
heart. This method uses isobaric tagging of cysteine thiols and mass spectrometry 
in a modified biotin switch on whole tissue lysate. Analyzing the resulting data 
with systems biology approaches helped delineate redox pathways playing a role 
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in disease development, while cysteine-specificity provided exact targets for 
mutation-based mechanistic studies.  
Initial findings in a mouse model for MetS, wherein C57Bl6J mice were fed 
a high fat/high sucrose diet, identified energy pathways as the primary target of 
changing reversible cysteine oxidation. In follow-up studies, our collaborators 
helped validate the pathophysiological role of two particular cysteines in complex 
II; their early reversible oxidation and later irreversible oxidation contributed to 
decreased ATP output from cardiac mitochondria.  
A subsequent, more robust study revealed a weakness in our original 
method. While investigating the role of hydrogen peroxide-induced oxidative 
post-translational modifications (OPTMs) in the development of MetS sequelae, 
analysis of four mouse groups, each with an n=5, revealed that measurements of 
reversibly oxidized cysteine thiols were highly variable compared to those of all 
available thiols. Thus, I developed a strategy to address the source of variability 
and, in the process, improved many additional steps in the switch protocol.  
Finally, in an effort to clarify the role of the most stable reversible OPTM, 
glutathionylation (RSSG), we characterized the HFHS diet response in mice 
engineered to have more or less RSSG via genetic manipulation of glutaredoxin-1 
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expression. Those with more RSSG suffered worsened cardiac function, making 
them an ideal model for future studies with the methods optimized in this work.  
Studying the progression from poor diet to cardiac involvement in these and other 
mouse models using the methods described herein will aid in the design of 
diagnostics and targeted therapies against the growing burden of metabolic CVD. 
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Background 
Cardiovascular disease (CVD) is the leading cause of death in the United 
States (Kochanek et al., 2011). More than a third of the US population is at 
increased risk for cardiovascular mortality (Mottillo et al., 2010) particularly due 
to metabolic syndrome. A person suffers from metabolic syndrome if they exhibit 
3 of 5 risk factors for CVD and diabetes, including: hyperglycemia, high blood 
triglycerides, central obesity, high blood pressure, and high cholesterol. It is 
imperative that we identify the molecular mechanisms behind diet-induced CVD 
so that we can develop targeted therapies and interventions to address this 
growing burden on our health and economy (Ambrosy et al., 2014; Go et al., 2014; 
Scholze et al., 2010; T. James et al., 2004). 
In humans, metabolic CVD primarily presents as diastolic dysfunction and left 
ventricular hypertrophy (von Bibra and St John Sutton, 2010; Garg et al., 2013). 
Treating diastolic heart failure (HF) with current available therapies designed for 
systolic HF has often led to neutral or, at least, inconsistent clinical outcomes 
(Paulus and van Ballegoij, 2010). Our lab has developed a model for diet-induced 
diastolic dysfunction whereby feeding C57BL/6 mice a high fat and high sucrose 
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(HFHS, 35.5% lard and 36.3% sucrose) diet, the mice develop left ventricular 
hypertrophy by 8 months, with changes in wall thickness detectable by 
echocardiography as early as 2 months (Qin et al., 2012). Furthermore, these mice 
exhibit impaired left ventricular filling and relaxation with preserved systolic 
function. Studying molecular changes induced by diet in these mice will identify 
new ways to prevent this type of cardiac remodeling, which accounts for 50% of 
hospital admissions for heart failure (von Bibra and St John Sutton, 2010). 
Increased systemic and heart-specific oxidative stress has been shown in humans 
patients with MetS, as well as in a multitude of animal models for diabetes, obesity, 
and hypertension [for a review of cardiovascular oxidative stress in MetS, see ref 
(Ilkun and Boudina, 2013). In this mouse model for metabolic syndrome, oxidative 
stress increases, as indicated by immunostaining of protein-bound 4-
hydroxynonenal and 3-nitrotyrosine in left ventricle sections. These and other 
oxidative post-translational modifications (OPTMs) are caused by reactive oxygen 
and nitrogen species (RONS) arising from leaky mitochondrial respiration, 
uncoupled eNOS, and NADPH oxidases. Chronic imbalance between antioxidants 
and RONS can be detrimental (Pacher et al., 2007) as accumulating modifications 
irreversibly change the functional capacity of enzymes. For example, tyrosine 
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nitration has been shown to inactivate manganese superoxide dismutase—an 
enzyme important for converting superoxide into less reactive hydrogen peroxide 
(Surmeli et al., 2010). Successive oxidation events can also convert transient 
oxidative modifications of cysteines into irreversible di- and tri- oxidation (R-SO2H 
and R-SO3H, respectively). An important case of irreversible modification 
significantly affecting heart function is tri-oxidation at Cysteine-674 of the 
Sarcoendoplasmic Reticulum Calcium Transporting ATPase (SERCA). This ATP-
dependent enzyme helps sequester calcium back into the SER at the end of a 
contraction, allowing for relaxation of cardiac muscle. Qin et al. showed that 
irreversible oxidation permanently inhibited SERCA activity, impairing relaxation 
and ventricular filling in the mouse heart (Qin et al., 2013). In obese insulin-
resistant Zucker rats (Tong et al., 2010), SO3H-mediated SERCA inhibition also led 
to abnormal smooth muscle and endothelial cell migration in response to vascular 
injury.  
While RONS are best known to induce damage and the aforementioned 
modifications serve as markers of stress, accumulating data supports an important 
role for RONS in redox signaling (Dröge, 2002). Nitric Oxide (NO), for example, is 
critical for regulation of vascular tone. It is only upon reaction with superoxide 
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that NO forms the highly reactive peroxynitrite, leading to irreversible adducts 
and decreased bioavailability of NO. In controlled amounts or acute bursts, RONS 
induce reversible modifications of cysteines, such as sulfenic acid (RSOH), S-
nitrosation (RSNO), S-glutathionylation (RSSG), and disulfides (RSSR), which 
help to maintain thiols in a dynamic state. This enables acute modulation of 
signaling pathways by increasing enzyme activities. Alternatively, it can 
transiently protect reactive sites from irreversible oxidation at the expense of 
temporary inactivation. For example, Chen et al. (2008) used in vitro experiments 
to demonstrate that reversible RSNO could prevent irreversible inactivating 
oxidation (SO2H and SO3H modifications) at the active site cysteine (215) of protein 
tyrosine phosphatase 1b, an important regulator of insulin signaling. Similarly, 
while SERCA can be inactivated by over-oxidation at C674, the Colucci and Cohen 
laboratories showed that RSSG at C674 of SERCA increased activity of the protein 
in adult ventricular myocytes treated with nitroxyl (Lancel et al., 2009). RSSG was 
also shown to increase the activity of cardiac carnitine o-palmitoyl transferase 1b 
(Cpt1b), an outer mitochondrial membrane protein that mediates the rate-limiting 
step of fatty acid transport into the mitochondria for β-oxidation (Sharma et al., 
2010). It would follow that this type of activity-changing modification may 
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modulate myocardial metabolism because energy-rich fat is the heart’s preferred 
substrate. 
In order to define RSNO substrates, Jaffrey et al. (2001) designed the biotin-switch 
assay. First, free thiols in a protein lysate were blocked by alkylation, RSNO thiols 
were specifically reduced with ascorbate, and then the newly freed thiols were 
alkylated with a reagent conjugated to biotin. Streptavidin-agarose pull-down was 
then used to enrich for biotinylated proteins and sites originally nitrosylated in 
vivo could be mapped using mass spectrometry (MS). Quantitative redox 
proteomics developed considerably once the Cohen and Costello labs applied 
isotope-coded affinity tags to the switch. This enabled relative quantitation of 
redox-sensitive cysteine thiols in multiple complex mixtures with just one MS run. 
(Sethuraman et al., 2004a, 2004b). Benhar et al. (2010) extended these types of 
assays by using recombinant thioredoxin-1 as an in vitro enzymatic reductant 
between the two labeling steps; this identified sites (primarily S-nitrosylated thiols) 
susceptible to regulation by Trx1. Newer quantitative switch assays using isobaric 
cysteine-reactive tandem mass tag (TMT, Thermo Fisher Scientific, Waltham, Ma) 
labeling and high resolution, high mass accuracy MS have emerged for studying 
the percent occupancy of SNO at cysteines (i.e. how much of a particular protein 
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in the cell is nitrosylated at one specific cysteine). These techniques were first 
described by Murray et al. (2012) in cell lysates treated in vitro and in vivo with an 
NO-donor then by Kohr et al. (2012) in the myocardium. The latter demonstrated 
an increase in the cysteine occupancy of SNO in many proteins under ischemic 
preconditioning of the heart. 
While labile RSNO has been studied intensively, it will be important to identify 
substrates more stably modified by RSSG, especially because both RSOH and 
RSNO can be exchanged for RSSG (Pimentel et al., 2012). Glutaredoxin (Glrx) is a 
thioltransferase similar to thioredoxin 1, but Glrx specifically reduces RSSG, 
whereas thioredoxin 1 can reduce RSSR and RSNO (Shelton et al., 2005). 
Investigating the role of Glrx in controlling global oxidative changes during the 
development of CVD would unveil new targets of glutathionylation and help to 
define mechanisms involved in oxidative stress-induced cardiac remodeling. 
Earlier efforts to investigate global changes in RSSG resulted in in situ detection of 
RSSG modified proteins in intact epithelial cells (Reynaert et al., 2006). The group 
used a Glrx-catalyzed switch in which cells were fixed and permeabilized, as in 
normal immunocytochemistry, then free thiols were blocked with N-
ethylmaleimide (NEM). Next, Glrx plus its necessary components (NADPH, 
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glutathione reductase, etc.) were applied to reduce RSSG proteins. Finally, a 
biotin-derived moiety was applied to alkylate newly free thiols and FITC-
conjugated streptavidin was used for visualization. The beauty of this method was 
that all reagents and enzymes could be rinsed away between each step so that they 
would not interfere with steps downstream. In the malaria parasite Plasmodium 
falciparum (Pf), Kehr et al. (2011) characterized the “glutathionylome” by applying 
a switch with Pf Glrx. They identified 493 RSSG targets. Very recently, groups have 
described the use of Glrx to mediate in-solution targeted reduction of RSSG in cell 
lysate (Su et al., 2014; Zhang et al., 2011), a procedure that has proven elusive in 
our lab as well as well as in the labs of collaborators. While these experiments are 
encouraging, identification of new substrates for Glrx and quantification of these 
oxidative modifications in the mammalian heart would be helpful to determine 
which are important during development of CVD pathology arising from 
metabolic syndrome. 
To identify relevant glutathione (GSH) modifications, particularly those that are 
enzymatically regulated, we are using transgenic mice globally deficient in or 
overexpressing Glrx. While the overarching goal in using these mouse models was 
to probe for important changes caused by decreases or increases in protein-
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glutathione modifications, respectively, the response by these mice to a variety of 
insults parallels the complexity of redox signaling itself. With biotin-switch 
techniques and pan-glutathione blotting, each experiment confirmed that Glrx 
controlled RSSG modifications in the expected direction. Whether this was helpful 
or not depended entirely on the context—organ system, insult, and timing. For 
example, Glrx overexpression improved both systolic and diastolic function in a 
mouse model of heart failure (Gαq overexpression)(ref: Fuzhong Qin in-house 
presentation). However, knocking out glrx in mice prevented cardiac hypertrophy 
caused by high-dose angiotensin II infusion (Bachschmid et al., 2010). It also 
protected against HFHS-induced increases in aortic pulse-wave velocity (ref: Colin 
Murdoch in-house data), a property of vascular stiffness and predictor of CVD in 
humans (Weisbrod et al., 2013). 
Interestingly, and conversely, knocking out glrx also led to obesity, hepatic 
steatosis, and hyperlipidemia by eight months in chow-fed mice. Reconstitution 
of Glrx in the liver by adenovirus normalized hepatic lipids (Shao et al., 2015). 
Together, these data suggest that chronic protein-glutathionylation disrupts lipid 
handling by the liver, revealing a potential mechanism by which these pathologies 
develop in metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). 
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One key point of metabolic control lies in Sirtuin-1 (SirT1) activity. This redox-
sensitive deacetylase regulates a variety of metabolic processes and has been 
shown to delay cardiovascular aging (Alcendor et al., 2007). Studies in our lab 
demonstrate that SirT1 loses activity when reversibly oxidized, as is the case in 8-
months old glrx KO mice. To mimic the metabolic perturbation seen in these mice, 
hepatocellular carcinoma (HepG2) cells in culture were treated with high 
palmitate/high glucose. In this system, the loss in SirT1 activity could be restored 
upon overexpression of Glrx. 
In the context of ischemia/reperfusion, glrx KO leads to improved outcome in the 
hind limb, while overexpression helps achieve the same result in the heart. After 
femoral artery ligation, GSH adducts were shown to increase in the ischemic limb 
of WT mice. These adducts appear to be critical for recovery, as glrx KO mice 
experienced increased blood flow recovery (Murdoch et al., 2014) while Glrx Tg 
mice experienced poorer blood flow and motor function following surgery. 
Endothelial cell-specific overexpression of Glrx led to decreased blood flow 
recovery and necrosis of the hindlimb (ref: Yosuke Watanabe in-house 
presentation), recapitulating the effects of the global transgene. To clarify the 
pathways involved, endothelial cells (ECs) isolated from WT and Tg mice were 
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tested for their response to a variety of factors including vascular endothelial 
growth factor (VEGF), tumor necrosis factor alpha (TNFα), and hypoxia. Human 
microvascular ECs infected with a virus encoding glrx were also used to model the 
poor response seen in Glrx TG mice. Soluble flt (sFlt), a decoy VEGF receptor that 
interferes with downstream pro-angiogenic events, was found to be upregulated 
in Glrx overexpressing systems. Inhibiting Wnt5a (wingless-type MMTV 
integration site family, member 5A), a non-canonical Wnt signaling protein that 
has previously been shown to control Flt splicing, prevented the Glrx Tg-
associated increase in sFlt and restored network formation (Murdoch et al., 2014). 
Accordingly, Wnt5a and sFlt were increased in ischemic muscle and plasma, 
respectively, in Glrx Tg mice as they attempted to recover from ischemia. Further 
studies demonstrated that the increase in Wnt5a and sFlt was due to Glrx 
catalyzing removal of important inactivating modifications on NFB-p65. 
Together, these data define a supportive role for GSH protein adducts in ECs for 
blood flow and muscle recovery following ischemia. 
In other studies, where coronary artery ligation was used to induce myocardial 
infarction, Glrx Tg mice recovered significantly more left ventricular function 
(increased ejection fraction and fractional shortening) than WT mice after thirty 
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days’ recovery (Adluri et al., 2012). Shortly after the surgery, arteriolar density was 
greater and both superoxide production and apoptotic signaling were attenuated 
in the Glrx Tg myocardium. While the researchers did not examine whether 
OPTMs directly affected NFB function in this study, they used electrophoretic 
mobility shift assay (EMSA)/gel shift analysis to show that in the ischemic 
myocardium of TG mice, NFB translocated to the nucleus and exhibited stronger 
DNA binding activity. They made an interesting hypothesis that increasing Glrx 
may help during ischemia in the myocardium by minimizing oxidative stress 
while still allowing NO and S-nitrosylation-mediated angiogenic signaling.  
Developing proteomics methods that can be applied in each context would 
advance our understanding of the pathways involved and help to clarify 
differences that contribute to varied outcomes. In addition to a systems biology 
view, redox MS in these Glrx-KO and Tg mice would afford site-specific 
quantitation of reversible cysteine oxidation (likely GSH adducts) on novel targets. 
Identifying the most robust changes accelerates downstream study into 
mechanisms of action and therapeutic potential. 
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Methods 
Mouse models 
Nicotinamide Nucleotide Transhydrogenase (Nnt) and metabolic syndrome 
When mouse strains were first acquired, they were on a mixed background of 
C57Bl6/NJ and J. C57Bl6/J mice have been used as a model for diet-induced obesity 
because they are more susceptible to developing insulin resistance and weight 
gain. Studies now show one of the main distinguishing factors between NJ and J 
is whether Nnt is mutated (Figueira et al., 2013; Nicholson et al., 2010; Ronchi et 
al., 2013). Nnt is a nuclear-encoded mitochondrial inner membrane proton pump 
that forms NADPH from NADP+ by converting NADH to NAD+. As a primary 
source of NADPH, Nnt supplies glutathione reductase with the reducing 
equivalents required to maintain the reduced glutathione pool in the matrix. 
NADPH is also used to maintain thioredoxin in a reduced state so that it can, in 
turn, maintain other antioxidant enzymes. Mice on J background lack functional 
Nnt making their mitochondrial redox balance tenuous, at best. Metabolic 
syndrome-induced diastolic dysfunction was first described using this mouse 
model and we used those hearts for our initial proteomics studies, so for 
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comparison purposes, we used only Nnt-mutant mice for the Glrx mouse studies 
and breeding. 
High Fat High Sucrose diet feeding 
Three to four month old mice were fed a normal chow diet (4.5% fat and 0% 
sucrose) or an HFHS diet (35.5% fat from lard, representing 60% calories, and 16.4% 
sucrose) ad libitum for approximately 7-8 months (D09071702 and D09071703; 
Research Diets, New Brunswick, NJ, USA). The control diet was custom 
formulated to match the micronutrients contained in the HFHS diet except for fat 
and sucrose. Mice were housed in rooms with a 12-h light-dark cycle and in groups 
of 3–4 whenever possible. The protocol was approved by the Institutional Animal 
Care and Use Committee at Boston University School of Medicine. Mice were 
euthanized after 8 months on the diets. 
Glrx Transgenic 
We acquired our Glrx Tg mouse strain (mixed background) from the Ye-Shih Ho 
lab at Wayne State University (Detroit, Michigan). These mice expressed human 
glrx under control of a human β-actin promoter. A postdoctoral researcher in our 
lab backcrossed these mice to C57BL6/J. 
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glrx Knock Out 
Original glrx KO mice were also generated by Ye-Shih Ho at Wayne State 
University (Ho et al., 2007). A vector encoding neomycin resistance (NEO) in place 
of exons 1 and 2 of glrx was transfected into R1 embryonic stem cells. For targeted 
insertion, on either side of NEO the vector coded for the 3.5kb 5’ flanking region 
of glrx and 3’ non-protein coding exon 3.  After clones were screened for targeted 
insertion, they were injected into C57BL/6 blastocysts. Chimeras contained the 
disrupted allele. These glrx KO heterozygote mice on a 129SV and C57BL/6 hybrid 
background were passed to the Yvonne Janssen-Heininger lab at University of 
Vermont, where they backcrossed these mice to C57BL6/NJ background. Finally, 
we obtained the mice and backcrossed them to C57BL6/J mice until all offspring 
generated expressed mutant Nnt. Occasionally a male homozygote KO (GlrxKO) 
could be used for breeding, but females needed to be heterozygote (Glrxhet) to 
breed successfully. Generally, Glrxhet mice were bred to produce GlrxKO and their 
GlrxWT littermate controls. 
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Genotyping 
Under isofluorane general anesthesia, administered in a bell jar, tail snips were 
taken and added to 200uL of tail digestion buffer (66mM Tris-HCl pH 8.8, 16.5mM 
(NH4)2SO4, 6.6mM MgCl2, 0.5% Triton-X) supplemented with 2uL β-ME and 8uL 
proteinase K from Tritirachium album (Qiagen, Valencia, Ca) or 2uL recombinant 
proteinase K (Thermo Fisher Scientific, Waltham, Ma). After overnight (O/N) 
incubation at 55°C, digestions were boiled for 10 minutes then centrifuged at 10k 
rcf for 10 minutes at 4°C. Supernatant was diluted 1:20 in water prior to PCR. Stock 
primer concentrations were 100μm in TE buffer. Prior to adding to PCR reaction, 
each pair of primers were mixed 1:1 and diluted to 10μm final concentration, 
except where noted. Primers for each genotype were as follows: 
glrx WT (20μm) 
INTRON5 – CCA GCT CTC AGG AGA TGA CC 
INTRON6 – AAA ATC CCA CAC CCC TTT TC 
Product size= 699 bp 
 
neomycin 
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Neo1 – GCT TGG GTG GAG AGG CTA TT 
Neo2 – GAA CTC GTC AAG AAG GCG ATA 
Product size= 750 bp 
 
nnt WT 
nnt-COM (F) – GTA GGG CCA ACT GTT TCT GCA TGA 
nnt-WT    (R) – GGG CAT AGG AAG CAA ATA CCA AGT TG 
Product size= 579 bp 
 
nnt Mutant 
nnt-COM (F) – GTA GGG CCA ACT GTT TCT GCA TGA 
nnt-MUT (R) – GTG GAA TTC CGC TGA GAG AAC TCT T 
Product size= 743 bp 
 
Glrx Tg (20μm) 
Sense-Coding – GAGCAAGAACGGTGCCTCGAGTCTTTATTGG 
Antisense-Untranslated – CACAGTGTTCAGGATTATCTGGATAGCCATC 
Product size= 309 bp 
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PCR reactions were prepared as described in Table 1: 
Cycling parameters varied depending on the primer set and enzyme master mix 
used. Parameters used are summarized in Tables 2-5. 
Following PCR, 10uL of each amplicon was loaded into a 1.2% agarose gel (in TAE 
buffer) containing GelRed Nucleic Acid Gel Stain and electrophoresed at 100V. 
Gels were imaged using trans-UV in a Bio-Rad gel doc (Bio-Rad, Hercules, Ca) 
with Quantity One (V. 4.6.9) software. Figure 1 contains representative gels and a 
key for interpretation. 
Table 1. Preparation of PCR reactions for genotyping. 
glrx Tg glrx WT and neo reactions nnt reactions 
1 uL Primer mix 0.5 uL Primer mix 1 uL Primer mix 
8 uL water 7.5 uL water 7 uL water 
10 uL Enzyme mix 10 uL Enzyme mix 10 uL Enzyme mix 
1 uL Sample gDNA 2 uL Sample gDNA 2 uL Sample gDNA 
20 uL 20 uL 20 uL 
 
Table 2. PCR cycling conditions for glrx Tg amplification using Maxima Hot 
Start Green PCR Master Mix (Thermo). 
Cycles Temperature (°C) Duration 
1 95 4:00 
35 
95 0:30 
63 0:30 
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72 1:00 
1 72 10:00 
1 4 ∞ 
 
Table 3. PCR cycling conditions for glrx Tg amplification using REDExtract-N-
Amp PCR ReadyMix (Sigma). 
Cycles Temperature (°C) Duration 
1 94 5:00 
35 
94 0:30 
60 0:30 
72 0:45 
1 72 5:00 
1 4 ∞ 
 
 
Table 4. PCR cycling conditions for glrx WT & neo amplification using 
Maxima Hot Start Green PCR Master Mix. 
Cycles Temperature (°C) Duration 
1 95 4:00 
30 
95 0:30 
54 0:30 
72 0:45 
1 72 5:00 
1 4 ∞ 
 
Table 5. PCR cycling conditions for glrx WT, neo, & nnt amplification using 
REDExtract-N-Amp PCR ReadyMix. 
Cycles Temperature (°C) Duration 
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1 94 5:00 
35 
96 0:30 
55 0:30 
72 0:45 
1 72 5:00 
1 4 ∞ 
 
 
Figure 1. Agarose gel of products from PCR of tail digestions. 
(A) Human glrx was amplified to produce an amplicon of 309bp; mice designated as 
“393”, “415”, and “425” were positive for the human transgene. (B) Top row contains 
amplicons from PCR using primers against the mutant form of nnt (743bp), the WT form 
of nnt (579bp), or glrx WT (699bp).  Bottom row contains products amplified by the 
following primers (in order from left to right): glrx WT, neo (750bp), glrx WT. Mouse 
designated as “5” is an example of nnt mutant. Mouse designated as “17” is an example 
of nnt WT. Mouse designated as “41” is an example of heterozygote for glrx KO, with 
one glrx WT allele and one neo allele. 
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Fasting Glucose Tolerance Test 
The night before the test, body weights were measured and 4 g was subtracted to 
approximate fasted weight. Mice were placed in fresh cages without food, but with 
their original water bottle, between 5 and 9 pm prior to starting the test between 9 
and 11:30 am the following morning. Cages were moved to a work space within 
the animal facility at least 45 minutes prior to start so that the mice could settle. 
General isofluorane anesthesia was applied in a bell jar prior to nicking tails to 
begin bleeding. Baseline glucose was measured by touching a drop of blood to a 
Contour Next Blood Glucose Test Strip (Bayer) inserted into a Contour® Next USB 
blood glucose meter (Ascensia Diabetes Care, Parsippany, NJ). 10uL of syringe-
filtered (0.2μm) 20% glucose per gram of fasted body weight was injected 
intraperitoneally and the timer started. Measurements were taken again at 15, 30, 
60, 90, and 120 minutes. 
Tissue harvest 
Mouse cages were moved from the animal facility to our lab the night before 
sacrifice. Under general isofluorane anesthesia, administered via bell jar and nose 
cone, mouse feet were pinched to ensure lack of consciousness. After dousing the 
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abdomen with 70% ethanol spray, the skin was cut open to reveal the intact 
diaphragm covering the beating heart. Using a 1mL syringe fitted with a 27g ½-
inch needle, mice were exsanguinated via cardiac puncture. Blood was preserved 
by adding to BD Microtainer® tubes (Franklin Lakes, New Jersey) containing 
EDTA and inverting 10 times. Next, mice were perfused with 12mL ice cold PBS, 
also using a 27g needle inserted into the apex of the heart. The whole heart was 
snipped out of the cavity and put into ice cold PBS, squeezed with forceps to 
remove any remaining blood from the chambers, and both atria were cut away 
from the ventricles. Any white material—vessels or pericardial fat—was also 
snipped away. The intact ventricles were blotted with a kim wipe prior to weight 
measurement. The heart was returned to ice cold PBS and the right ventricle was 
carefully cut away from the mass of the left ventricle. After cutting the left ventricle 
into four pieces and dividing them two to a cryotube, they were flash frozen in 
liquid nitrogen and stored in a liquid nitrogen tank. One hind limb was cut above 
the knee, wrapped in foil, and frozen at -20°C to keep for tibia length measurement 
by X-ray. Many other organs were also snap-frozen, added to TRIzol® (Thermo 
Fisher Scientific, Waltham, Ma), or to formalin, for use in protein assays, mRNA 
quantitation, or staining, respectively. 
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Tissue homogenization 
First iodo-TMT-labeling proteomics experiment  
Left ventricle pieces were thawed enough to cut into two, weighed and split to 
separate ice cold M-tubes pre-rinsed with acetonitrile. Nonidet P-40 buffer (1% 
NP40 (IGEPAL CA-630; Calbiochem/EMD Biosciences, Darmstadt, Germany), 
50mM Tris pH between 7.4 and 8.0, 150mM NaCl, 1mM EDTA (Sigma, St. Louis, 
MO, USA), Roche Applied Science (Indianapolis, IN, USA) cOmplete® mini 
protease inhibitor tablet at 1/10ml) was added at 300uL per 5mg tissue wet weight 
and supplemented with either 50mM iodoacetamide  (IAM) or 1mM TCEP (Tris(2-
carboxyethyl)phosphine). Two 54-second “Protein_01” cycles on the gentleMACS 
dissociator (Miltenyi Biotec, Cologne, Germany) were used for homogenization. 
After brief cold centrifugation, homogenates were moved to Eppendorf tubes and 
rotated at 4°C for 2.5hrs. IAM samples were maintained in dark with foil. After 
incubation, tubes were spun hard for 10 minutes at 4°C then supernatant was 
moved to fresh tubes and pellet discarded. 
Cardiac Catalase Transgenic (Cat Tg) mouse iodo-TMT proteomics study (n=5) 
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Samples were processed as described above, except for select modifications made 
in an attempt to improve the protocol. Left ventricle pieces were homogenized in 
only 300uL of buffer to maintain high protein concentration. 0.5mM DTPA was 
substituted for EDTA for stronger chelation. Homogenization cycles were 
completed in a cold room (4°C) and breaks on ice were added between cycles. To 
minimize foaming, no detergent was included during homogenization, but rather, 
acid-labile, rapidgest was added to 0.125% after samples were moved to 
Eppendorf tubes. NP40 was omitted.  
Final protocol for ratio-adjusted TMT experiment 
2% SDS and 0.5% Na Deoxycholate were supplemented to the first 
homogenization buffer (HB) and 0.1mM DTPA was substituted for EDTA. 50mM 
NEM was used instead of IAM. TCEP was increased to 10mM at each step. Instead 
of using the gentleMACS dissociator and the excessively large M-tubes, left 
ventricle pieces were homogenized with 2mm ceramic beads in 2mL screw cap 
tubes (Mo Bio laboratories, Carlsbad,Ca) using a MagNAlyzer (Roche, 
Indianapolis, In) at 6000rpm for four 20-second cycles. Between each cycle, tubes 
were stored on ice for 3 minutes then gently centrifuged. After a five minute 3.5k 
rcf centrifugation, samples were sonicated for approx. 15 pulses with a probe 
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sonicator set to 20% duty cycle and output 2. Samples were NEM-blocked for only 
20 minutes with rotation at RT before a10k rcf centrifugation for 10 minutes at 4°C. 
Gel filtration desalting of protein samples 
Before optimization of the switch with precipitation (pptn) for desalting steps, gel 
filtration columns with a 7kDa molecular weight cutoff (Zeba™ Spin Desalting 
Columns; Thermo Pierce, Rockford, IL, USA) were used to remove small 
molecules, like IAM. In the first TMT experiment, columns were equilibrated three 
times with 5% ACN (acetonitrile) + 0.005% ProteaseMax™ Surfactant (Promega, 
Madison, WI, USA) in Tris-buffered saline (TBS) and were only used on the IAM-
blocked sample. For the Cat Tg mice, conditions were kept the same for both IAM-
blocked and TCEP conditions, desalting each with Zeba™ columns after 
equilibration with 5% ACN+0.01% ProteaseMax™ in TBS. 
Reduction, TMT-labeling, multiplexing, and acetone precipitation 
Following TCEP reduction for about 1 hour at 37°C, samples were labeled with 
approx. 3mM iodo-TMT for two hours at room temperature (RT). In the Cat Tg 
study and ratio-adjustment experiment, the labeling reaction was quenched with 
10mM DTT for 5 min at RT. For the first two studies, 100ug of protein from each 
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labeled sample were mixed together then precipitated. For the ratio study, 200ug 
of each NEM-blocked-then labeled sample was mixed with approx. 30.3 ug of each 
completely reduced-then labeled sample prior to pptn. Four parts 50% acetone in 
ethanol (or in water for Cat Tg) plus 0.1% acetic acid was added to one part sample 
and incubated at -20°C O/N.  
Resuspension, digestion, and TMT-peptide precipitation 
For the first two studies, the precipitated protein was resuspended in 0.05% 
protease max in TBS then digested O/N at 37°C with trypsin gold (Promega, 
Madison, WI, USA) at a ratio of 1:20 ug trypsin to protein. For the final protocol, 
samples were resuspended in 6M Urea in Tris pH 8 so that Lys-C (1:25 
LysC+trypsin gold; Promega, Madison, WI, USA) digestion could proceed first for 
3-4 hours. Then samples were diluted 6-fold so that trypsin would be active for an 
O/N 37°C digestion. Trypsin reaction was stopped upon addition of formic acid. 
Samples without urea were vacuum concentrated (Savant SpeedVac, Thermo 
Fisher Scientific, Waltham, Ma) to dryness then resuspended in TBS prior to 
adding resin. Samples containing urea were simply neutralized to pH 8 with 
ammonium hydroxide. Peptides were precipitated (2hr at RT to) O/N at 4°C with 
pre-washed immobilized anti-TMT (antibody) resin at a ratio of 1:1 ug protein to 
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uL resin. In the earlier protocol, after immunoprecipitation, resin was washed 3 
times with TBS, 4 times with 4M Urea in TBS, and 4 times with water, each rotated 
for 5 minutes at RT. For the final protocol, resin was washed 5 times with one 
column volume of 2M Urea in TBS, 3 times with TBS, and 3 times with water. 
Finally, peptides were eluted four times with one column volume of TMT elution 
buffer. Elutions were pooled and vacuum concentrated to near dryness. 
Reverse-phase Peptide desalting 
To preserve the columns in line with the mass spectrometer and minimize small 
molecules that can suppress ionization, peptide samples must be desalted. Nest 
group C18 columns enable easy desalting based on the hydrophobicity of peptides. 
These columns contain long hydrophobic carbon chains (C18) that strongly bind 
peptides under aqueous acidic solutions, such as 2% ACN and 0.5% formic acid in 
HPLC-grade water. The aqueous solution is considered the mobile phase and the 
column material the stationary phase. Peptides partition from the mobile phase to 
stationary, so the same aqueous solution can be used to wash the peptides, 
removing salts in the flow-through. Importantly, supplementing the aqueous 
resuspension and equilibration solution with 0.1-0.5% formic acid helps neutralize 
peptides (H+ reacts with COO- and formate with NH3+); otherwise, polar peptides 
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would poorly bind the hydrophobic resin. After washing, 30% and 70% ACN is 
added to induce desorption of peptides back to the mobile phase (in this case, the 
highly organic solution). Depending on their specific properties (amino acid 
functional groups), certain peptides will elute with lower organic percentage, 
while others will need a more highly organic mobile phase for desorption. Note: 
These specific columns need to be “wet” first with 100% organic solvent before 
equilibration with the same aqueous solution in which the peptides are suspended. 
Reverse Transcription- qPCR 
Snap frozen tissue was added to 2mL screw cap tubes filled to the 0.5mL mark 
with 2mm Zirconia beads (Biospec, Bartlesville, OK ) and 1mL TRIzol® (Thermo 
Fisher Scientific, Waltham, Ma). After three 20 second cycles at 6000rpm on the 
MagNA Lyser (Roche, Indianapolis, In), with incubation on ice between, 
supernatant was moved to fresh tubes. 200uL chloroform was added to samples, 
followed by inversion to mix and 5 minute incubation at RT. Centrifugation at 12k 
rcf for 15min at 4°C separated the sample into three layers: clear top layer 
containing RNA, white middle layer containing DNA, and red bottom layer 
containing protein. Avoiding the white middle layer, supernatant was moved to 
fresh tubes containing 600uL isopropanol. Samples were inverted well to mix and 
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incubated at RT for 10 min. This precipitates nucleotides, including both DNA and 
RNA. After another hard, 10 min centrifugation to pellet the precipitated 
nucleotides, about 800uL of 80% ethanol was added, samples inverted and flicked, 
then incubated for 5-10min at RT to wash the pellet. One more 16k rcf, cold 
centrifugation pelleted the nucleotides, wash was discarded, and samples left 
open to lightly dry. An Ambion TURBO DNA-free kit (Thermo Fisher Scientific, 
Waltham, Ma) was used to digest and remove any remaining DNA. Nanodrop 
was used to quantify RNA content in order to dilute samples to 1ug/uL. The 
Applied Biosystems High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific, 
Waltham, Ma) was used to reverse transcribe RNA. A master mix containing 10uL 
Taqman master mix (ABI), 8 uL water, and 1uL cDNA was prepared for each 
sample. 19uL of each master mix was added to the bottom of wells in an ABI 96-
well plate, followed by 1uL of Taqman primer (described in Table 6). Plates were 
sealed with MicroAmp optical adhesive film. StepOnePlus instrument and 
software were used to run comparative CTCΔΔCT quantitation, with RPS18 as the 
endogenous control.  
For each sample, ΔCTmean for gene X was calculated by subtracting the 
endogenous control gene CT from gene X CT. The relative quantification (RQ) was 
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calculated using the following formula: 2^-( ΔCTmean  unknown sample  –  
ΔCTmean control sample). Finally, RQ was compared between samples for each 
target gene (Figure 40). 
Table 6. Catalog numbers for Thermo Taqman primers. 
FAM Taqman Primer (Thermo) Gene 
Hs00829752_g1 glrx Human glrx 
Mm00728386_s1 Mouse glrx 
Mm02601777_g1 Mouse rps18 
Western Blotting 
In general, approximately 30 ug protein lysate was added in a 6:1 (v:v) ratio to 6x 
reducing SDS-Sample buffer (Boston BioProducts, Ashland, Ma) supplemented 
with extra β-ME. If probing for glutathione adducts, samples were added in a 4:1 
(v:v) ratio to 4x nonreducing Pierce™ LDS sample buffer (Thermo Fisher Scientific, 
Waltham, Ma). After boiling for about 8 minutes, samples were loaded into pre-
cast gels (Bio-Rad, Hercules, CA, USA) in fresh 1x Tris-Glycine-SDS buffer. 
Depending on the size of proteins of interest and number of samples, different gels 
were used. The variety of percentages used included: 4-15%, 10%, 4-20%, any-kD, 
and 7.5%. A Mini-PROTEAN Tetra Cell was used to run mini-protean gels at 75V 
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for the first 15 minutes then 130V for about 60 minutes. Particularly to resolve Glrx, 
4-12% Bolt® Bis-Tris Plus gels from Invitrogen and the associated mini tank were 
required. The Bio-Rad Criterion system and precast TGX gels were used for 
comparing large numbers of samples. For all gels, proteins were transferred to 
polyvinylidene fluoride (PVDF) in transfer buffer (1xTris Glycine with 20% 
Methanol (MeOH) in deionized (DI) water) at 100V for 70+ minutes (or 13V O/N 
or 300A for 2 hours) at 4°C. Ponceau stain was used to check for transfer success. 
Also, the staining could be used to cut blots between different marker sizes in 
order to separately probe different proteins on the same blot. Blots were blocked 
in 3 to 5% milk in PBST (Phosphate Buffered Saline with 0.1% Tween) for 1 hour 
at room temp or O/N at 4°C. After rinsing with DI water and PBST, blots were 
probed with primary antibody, usually diluted at 1:1000 in 3% bovine serum 
albumin (BSA) in PBST, for 1 hour at RT or O/N at 4°C. Blots were washed with 
PBST four times for 8-10 minutes each before probing for one hour at RT with 
secondary antibody specific to the primary source species. If horseradish 
peroxidase-conjugated (HRP-) antibodies were used, these were diluted in 3% 
milk at 1:3000. If IRDye® (LI-COR Biotechnology, Lincoln, NE) secondary 
antibodies were used, they were diluted at 1:10000. When using two different 
IRDye® antibodies on the same blot, 680RD was used for the more abundant 
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protein and 800CW was used for proteins that required greater sensitivity for 
detection. In the case of streptavidin probing, no primary antibody was required. 
Secondary antibodies (HRP- or IRDye®) conjugated to streptavidin were used 
directly after blocking to probe for biotin labeling (i.e. reversible oxidation). Finally, 
blots were washed again as before, then imaged using Amersham (GE Healthcare 
Life Sciences, Pittsburgh, PA) or SuperSignal West Dura Extended Duration 
Substrate (Thermo Fisher Scientific, Waltham, Ma) enhanced chemiluminescence 
(HRP) or LI-COR (IRDye®). 
Plasma Cholesterol and Triglyceride measurements 
Blood samples captured in BD Microtainer® EDTA tubes were centrifuged at low 
speed (3-4k rcf) for 3-4 minutes to pellet red blood cells. The supernatant (plasma) 
was separated to fresh tubes, snap frozen, and stored in liquid nitrogen or at -80°C. 
Upon thawing, samples were vortexed and 3uL was added to one well in a 96-well 
clear flat-bottom costar plate. 300uL of Infinity Cholesterol or Triglyceride liquid 
stable reagent (Thermo Fisher Scientific, Waltham, Ma) was added to each well 
and the plate was incubated at RT for 5 minutes. The plate was read at 500nm. A 
standard curve from 50, 100, and 200 mg/dL was used to calculate values for each 
plasma sample. When many samples were assayed at once, the small 3uL sample 
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volume dried on the bottom of the plate, necessitating full resuspension by pipette 
once the reagent was added—a gradient of color was visible from bottom to top of 
each well prior to resuspension. 
Mass spectrometry 
Shotgun proteomics applies analytical chemistry to identify and characterize the 
protein components in a complex biological sample. In contrast to a “top-down” 
approach, wherein (relatively) pure intact protein is injected into a mass 
spectrometer for analysis, this method uses a “bottom-up” strategy. Proteins from 
a tissue sample are first digested into peptides by specific endopeptidases with 
known cleavage patterns (e.g. trypsin, which cuts c-terminal to arginine and 
lysine). The peptides are injected into the mass spectrometer and ionized by an ion 
source. These ions have distinct mass-to-charge ratios (m/z) which affect the path 
traveled through a field of high voltage induced within a vacuum. A mass 
analyzer detects the pattern of movement by each ion and transforms the signal to 
m/z. By comparing the thousands of m/z values measured from the sample to a 
public database of tryptic peptides from all proteins in the sample source species, 
the most probable protein content is calculated. The abundance of different 
proteins can also be inferred by the signal intensity of their corresponding peptides. 
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While mass spectrometer technology is highly advanced and improving every 
couple years, it is still limited in how many m/z measurements it can make on a 
finite complex sample at one time. It follows that it is easier for the instrument to 
“see” and measure the more highly abundant species. To deal with this, the 
parameters in the instrument can be set so that it excludes a previously measured 
species for a prescribed amount of time so that it can measure less abundant 
species concurrently flowing through the instrument. This is referred to as 
dynamic exclusion. However, this technique alone does not provide a sufficiently 
rich dataset. One way to reduce the complexity of the sample so that more 
components can be thoroughly measured is by fractionation, either subcellular or 
via separation according to protein characteristics like charge, hydrophobicity, 
and size. Subsequently, all fractions can be run separately; but this requires a lot 
of extra instrument and sample preparation time. By combining a very fast, high 
mass accuracy instrument like the Q Exactive (Thermo Fisher Scientific, Waltham, 
Ma USA) with reverse phase ultra-performance liquid chromatography (RP-UPLC; 
150 μm × 100 mm, packed with 1.7-μm, 130-Å BEH C18 material; Waters Corp., 
Milford, MA, USA) in line upstream of sample injection and ionization, a 
compromise can be reached between time/resources and dataset richness. 
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RP-UPLC separates the components of a complex peptide sample according their 
hydrophobicity in a similar way to the reverse phase desalting columns, but in line 
with the mass spectrometer and using a continuous gradient of solvent for 
ongoing elution of different species throughout the analysis. The column is tightly 
packed with sub-2μm particles that serve as a matrix for C18 chains to which the 
peptides bind under aqueous acidic solvent conditions at the beginning of the run. 
The small particle size allows for higher flow rates and resolution of more peaks 
(species) per unit time (Swartz, 2005). To allow higher flow rates, UPLC systems 
are capable of withstanding and maintaining extremely high pressure. After 
eluting off of the column, sample must be injected into the mass spectrometer; we 
use the triversa nanomate (Advion, Ithaca, NY, USA), which is a silica-based 
nanospray microchip with hundreds of tiny special nozzles to switch between for 
injection of different samples without carryover. Also, in the case of a clog, the 
chip automatically switches nozzles to prevent backpressure buildup and allow 
the run to continue uninterrupted, preventing sample loss. Furthermore, this chip-
based electrospray technology helps improve efficiency and stabilize the spray 
during ionization (1.65 kV) of the analyte. 
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One more level of analysis is required for accurate identification of peptides from 
a complex tissue homogenate that contains hundreds of proteins. Many peptides 
could have essentially the same m/z just by containing the same amino acids, but 
in a different sequence. Also, a shorter peptide with a modification on one of its 
amino acids may have the same m/z as a different longer peptide without a 
modification. MS2 peptide sequencing enables accurate sequence identification 
and residue-specific localization of modifications. This, in turn, allows for higher 
confidence protein matches. MS2 peptide sequencing is accomplished with LC-
MS/MS. After the first MS analysis of in-tact peptide masses, or precursor ions, the 
top 10 (or desired number) most abundant ions are picked for further analysis. In 
our method, we used collision-induced dissociation, wherein the precursors are 
trapped and fragmented by high energy collision (bombardment; 35V) with a gas 
such as nitrogen. In the ideal case, a peptide is fragmented into a full series of b- 
(from the n-term) and y- (from the c-term) ions which can then be measured by a 
second MS analysis (see Figure 2; Figure 5 from ref (Sverdlov et al., 2014)). Both 
MS measurements and the high energy collision between them occur within the Q 
Exactive. 
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Figure 2. MS2 peptide sequencing. 
Full series of b- (n-terminus) and y- (c-terminus) ions of the theoretical peptide ABCDEK. 
In MS2 peptide sequencing, peptides (precursor ions) are fragmented by collision-
induced dissociation, creating b- and y-ions for a second round of MS. These ions can be 
used to determine the sequence of the precursor as well as the localization of post-
translational modifications. Each of the theoretical fragments of this peptide (A, AB, … 
EK, K, etc.) are of a distinct sequence and mass and are detected as separate peaks in a 
mass spectrum from MS2. 
 
Cysteine labeling for multiplex quantitation with mass spectrometry 
With specific MS-compatible labeling techniques, we are able to analyze one step 
deeper during the discovery phase. To derive quantitative information about the 
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degree of cysteine oxidation in the whole cardiac proteome, we are using isobaric 
cysteine-reactive tandem mass tags (iodo-TMT). These may be used for parallel 
labeling of up to 6 different samples, which allows for identical workup, digestion, 
and mass spectrometric analysis (“multiplexing”). The isotope-coded tags contain 
2 heavy isotopes 13C and 15N at 5 positions in varying combinations across the mass 
normalizer and mass reporter regions (10 potential sites for heavy label indicated 
by asterisks; Figure 3). All 6 intact tags have the same total mass and structure (m/z 
457.33), except for the location of the heavy isotopes. This increases sensitivity for 
precursor ions  
because all six differentially labeled samples contribute to the same peak in MS1, 
increasing signal intensity for any intact TMT-tagged peptide. Differentiation 
between reporter ions depends on the number of heavy labels in the reporter 
region, left of the fragmentation site. Upon fragmentation in a tandem mass 
spectrometer (MS2), the signal intensities from the specific TMT-derived reporter 
ions in the range of m/z 126–131 represent the degree of cysteine labeling for each 
sample or condition. These are used in the switch protocol in place of cysteine-
reactive biotin label. Another benefit to this technology is the enrichment step it  
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Figure 3. Anatomy of the iodoTMTsixplex™ isobaric label reagents (Thermo-pierce, 
Cat No.: 900102).  
The Cys-reactive group attacks thiols in cysteine-containing proteins, forming a 
covalent bond between the label and protein.  These labels contain two heavy isotopes 
13C and 15N at five positions in varying combinations across the mass normalizer and 
mass reporter regions (10 potential sites for heavy label indicated by asterisk). All six 
intact tags are identical in structure, except for the location of the heavy isotopes, and 
add the same modification mass (329.2 Da) to peptides. Thus, any differentially labeled 
peptide that arises from multiple samples will have the same mass as it enters the mass 
spectrometer for MS1. Differentiation of the samples occurs after fragmentation of 
peptides in the instrument, which releases reporter ions whose mass depends on the 
number of heavy labels in the reporter region [left of the fragmentation (ETD/CID) site]. 
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In MS2, these reporters are detected in the low mass region of the mass spectrum, at m/z 
126, 127, 128, 129, 130, and 131 Da. 
 
affords—by immunoprecipitation of TMT-labeled peptides, the peptide mixture is 
simplified to reactive cysteine-containing peptides.  
TMT Data Analysis Parameters in PD 
The following parameters were used in PD: Only peptides with a q value < 0.01 
(high confidence). Peptides must contain a modification. Quantification 
parameters were as follows: Ratio Calculation tab--Do not replace missing Quan 
values with minimum intensity; Apply quan value corrections defined by the lot-
specific literature; Do not reject all quan values if not all quan channels are present; 
Percent co-isolation excluding peptides from quantification: 30. Protein 
quantification tab—Consider proteins groups for peptide uniqueness; Use all 
peptides. Experimental bias—None. 
Results and Discussion 
Searching for biomarkers of metabolic cardiovascular disease 
While metabolic syndrome increases the risk of developing diastolic dysfunction 
and heart failure, not all patients with MetS experience cardiovascular 
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complications (Benetos et al., 2008). Biomarkers for subclinical cardiovascular 
involvement would help distinguish which patients need closer monitoring and, 
potentially, intervention to stop disease progression. The ideal biomarker is easy 
to sample, stable, and very specific, so our ultimate goal was to find a specially 
modified protein in plasma that is specifically released by a heart undergoing the 
early stages of remodeling. Because MetS patients experience increased oxidative 
stress (Bugger and Abel, 2008; Ilkun and Boudina, 2013), which is recapitulated in 
the HFHS-fed C57Bl6J mouse model for MetS (Qin et al., 2012), we aimed to 
identify associated changes in oxidative modifications of proteins using 
proteomics. Usually, quantitation follows discovery in proteomics experiments, as 
each endeavor requires different types of instrumentation and workflow. 
However, the biomarker we were looking for would be defined by quantitated 
changes in OPTMs. Thus, we designed a semi-quantitative discovery proteomics 
approach, incorporating a modified “biotin-switch” with cysteine-reactive tandem 
mass tags and bottom-up MS. 99% of the protein mass in human plasma is 
comprised of only 22 proteins (Tirumalai, 2003), so it follows that our target is 
likely in the tiny 1% fraction of low abundant proteins. Furthermore, the range 
between the highest and lowest abundant proteins identified so far is greater than 
ten orders of magnitude (Anderson, 2002). To beat these odds, we decided to first 
 42 
 
identify changes in the myocardium of mice with highly developed MetS sequelae. 
Subsequently, plasma could be mined using a targeted approach (i.e. 
immunoprecipitation and multiple reaction monitoring MS). 
The biotin-switch is the classic method used to measure changes in reversible 
protein cysteine oxidation. First, free thiols are alkylated (locked down, blocked) 
during homogenization. This prevents scrambling of disulfides and other 
oxidative modifications. It also prevents artificial oxidation, commonly induced 
during sample preparation, of endogenously unmodified sites. Next, all reversibly 
oxidized thiols are reduced with an indiscriminate reducing agent, such as 
dithiothreitol (DTT) or TCEP. Alternatively, as first demonstrated by Jaffrey and 
colleagues (Jaffrey and Snyder, 2001), one can specifically reduce nitrosylation 
with ascorbate. The specificity of ascorbate is controversial, nitrosylation is 
extremely labile, and years of optimization have followed (Forrester et al., 2007, 
2009; Huang and Chen, 2006). Recent studies have shown that ascorbate with 
copper (I) can react with sulfenic acids, leading to false positives for nitrosylation 
(Reisz et al., 2013). Another specific switch that has been published but not yet 
widely practiced is the Glrx-mediated switch, which removes glutathione adducts 
(Su et al., 2014). Regardless of the reduction approach applied, the newly freed 
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thiols are then labeled with a cysteine-reactive tag. Two commonly used tags 
include Biotin-HPDP, which forms a reversible disulfide bond with the cysteines, 
and biotin-iodoacetamide (BIAM), which reacts irreversibly. Levels of reversibly 
oxidized proteins can then be compared between samples by Western blotting 
with a streptavidin-conjugated horseradish peroxidase or Licor dye. Alternatively, 
biotin-labeled proteins can be enriched using streptavidin-beads followed by 
elution and Western blotting with an antibody specific for a target protein. The 
relative level of reversible oxidation of that protein can be compared between 
beads from various samples. 
Sites of changing oxidation in metabolic heart disease 
We modified the classic protocol for use with 6-plex iodo-TMT tagging to enable 
site-specific quantitation of cysteine thiol oxidation throughout the proteome with 
MS. By preparing two separate homogenates of each mouse sample in parallel, 
with one completely reduced up front (total available thiols) and the other blocked 
(as usual, for reversible oxidation), we developed a novel method for quantifying 
thiol occupancy. Thiol occupancy is defined by the ratio of reversibly oxidized 
thiol to total available thiols for a particular protein cysteine in cells or tissue. 
Previous investigations into reversible oxidation have commonly compared 
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relative differences, requiring additional methods to account for any changes in 
expression. Not only does our method normalize for expression changes within 
the same run (represented by total available thiols), it also further defines the 
magnitude of change. For example, other studies may show that reversible 
oxidation at a particular cysteine increased by 2-fold under treatment conditions, 
but it is impossible to tell whether this fold-change was due to a 4 to 8 percent or 
30 to 60 percent increase. Thiol occupancy (described here as “percent oxidation”) 
is important for differentiating regulatory cysteines affected by metabolic disease. 
To determine the baseline of total available (free and reducible) thiols in this first 
study, the left ventricles from 3 different chow-fed mice were completely reduced 
during homogenization; these were pooled and labeled with TMT 126. To label 
only reversibly oxidized thiols, the other half of each of these same left ventricles 
was lysed in IAM to block all free thiols with an alkylating group comparable in 
chemistry and reactivity to iodoTMT labels. Reversibly oxidized cysteines were 
then reduced and labeled with TMT 127. Hearts (n=3) from mice fed a Western 
HFHS diet were processed accordingly, but labeled with TMT 128 and TMT 129, 
respectively. Tagged samples were pooled, precipitated to remove excess tag and 
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detergent, digested with trypsin, anti-TMT immunopurified to enrich for tagged 
peptides, and analyzed using a Thermo Q Exactive MS/MS system (See figure 4). 
We applied conservative rules in the analysis of this initial dataset.  First, Proteome 
Discoverer (PD; Thermo Fisher Scientific, Waltham, Ma) was used to derive raw 
ion intensities for each reporter ion from each individual MS/MS spectrum (event). 
The following exclusions of peptide events were applied: peptide was not 
assigned to a protein; peptide was not modified with an IodoTMT label; any of the 
4 reporter ions were not detected; and ratios generated by PD for quantitation of 
reporter ions suggested >100% or <1% reversible thiol occupancy (above or below 
the quantitation threshold according to PD). These were regarded as labeling or 
data processing artifacts. Furthermore, we could not  
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Figure 4. Tandem mass tag-switch labeling strategy (TMT-switch). 
(A) The 6-plex iodoTMT™ tags contain the two heavy isotopes 13C and 15N at five 
positions in varying combinations across the mass normalizer and mass reporter 
regions (10 potential sites for heavy label indicated by asterisk). All six intact tags have 
the same total mass and structure, except for the location of the heavy isotopes. 
Differentiation between reporter ions depends on the number of heavy labels in the 
reporter region [left of the fragmentation (ETD/CID) site]. (B) To determine the baseline 
of total available (free and reducible) thiols, the left ventricles from three different 
control animals were completely reduced; these were pooled and labeled with TMT 126. 
(C) To label only reversibly oxidized thiols, the other half of each of these same left 
ventricles was lysed in iodoacetamide to block all free thiols with an alkylating group 
comparable in chemistry and reactivity to iodoTMT tags. Reversibly oxidized thiols (i.e. 
-SG and –OH, but not SO3) were then reduced and labeled with TMT 127. Hearts (n = 
3) from mice fed a Western diet (HFHS) were processed accordingly, but labeled with 
TMT 128 and 129, respectively. (D) Tagged samples were pooled, precipitated to 
remove excess tag and detergent, digested with trypsin, anti-TMT immunopurified to 
enrich for tagged peptides, and analyzed using a Thermo Q Exactive tandem mass 
spectrometer system. 
 
interpret ∼15% of the peptides that passed the above exclusion criteria due to 
variable methionine oxidation, variable alkylation by IAM, and variations in 
missed cleavage sites. Peptides that contained more than one cysteine were 
included, but these values could only be considered a sum of the changes across 
all the labeled thiols. Raw ion intensities for each individual reporter were then 
summed from all included events for a single precursor ion (each detection and 
fragmentation event for a particular peptide). This is a departure from how PD is 
designed to quantify these tags. Usually, PD will calculate the ratio of two 
specified tags in each event spectrum and then report the median value of these 
ratios for each peptide. If there are an odd number of measurements for one ratio, 
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then it will report the geometric mean of the two middle values. Under discovery 
conditions, the goal was to acquire data on as many peptides as possible. This 
meant that precursors may only have been sampled a couple times for MS2 before 
the instrument switched to measuring other abundant ions present. Ideally, if 
there is not enough time to sample the entire elution window for a particular 
precursor (one peak in the extracted ion chromatogram; Figure 5, A), the most 
accurate sampling would be in the middle of the peak. This is where the largest 
amount of that precursor is eluting off the column, leading to maximum peak 
intensity. To give greater weight to signal from ions closer to the center of the peak 
(higher and more accurate intensities; Figure 5, B), we summed the raw ion 
intensities from each event, then calculated the ratio. With the raw intensity sums 
for each reporter, the following ratios were generated: 127/126 (percentage 
reversible oxidation in control group heart), 129/128 (percentage reversible 
oxidation in HFHS group heart), and 128/126 (total available thiols in HFHS 
compared with control group hearts). Fold change in oxidation was determined 
using the ratio of percentage reversible oxidation in HFHS over control group for 
every peptide.  
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The 98 proteins containing cysteines whose level of oxidation changed 
significantly (≥1.5-fold) with the HFHS diet were subjected to Ingenuity Pathway 
Analysis (IPA; Ingenuity Systems, Inc., Redwood City, CA, USA,  
 
 
Figure 5. Demonstration of peak sampling with an extracted ion chromatogram of a 
precursor ion with m/z 665.6800. 
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Peptide is eluting off the column between minute 17 and 18 of a run. Red vertical lines 
indicate “samplings” of the precursor ion for fragmentation and MS2. The precursor ion 
intensity increases over time until most of the ion has eluted off the column, at which time 
(approx. 17.5 min) the peak intensity begins to decrease. (A) representation of ideal 
conditions wherein the entire peak is sampled at even intervals for fragmentation and 
MS2. (B) actual conditions in discovery mode. Precursor was sampled two times, with the 
earlier sampling at lower intensity and the second at higher intensity. If resulting 
intensities were summed, a greater proportion of the total signal would derive from the 
second sampling. 
http://www.ingenuity.com). Because the software can only analyze 1 data 
point/protein, the largest fold-change peptide for any protein containing multiple 
significantly affected cysteines was used. The analysis used the Ingenuity 
Knowledge Base containing direct and indirect relationships derived from all 
wild-type and mutant and cell and tissue data from mice, rats, and humans. 
Endogenous chemicals were also included. 
Proteomic assessment of cysteine oxidation in hearts from mice fed a Western 
diet 
Of 455 proteins detected in lysates of the left ventricles of 3 mice fed an HFHS diet 
and 3 fed control diet for 8 mo, cysteine thiol occupancy could be differentially 
quantified in 173 proteins. A 1.5-fold-change cutoff in site occupancy was chosen 
to denote differences in cysteine oxidation of proteins from HFHS-diet-fed 
compared with chow-fed mice. HFHS diet altered cysteine oxidation within 112 of 
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the 270 quantifiable cysteine-containing peptides (Table 7). Of proteins with a 
change in site occupancy, 44% were mitochondrial, 23% were cytoplasmic and/or 
nuclear, and 33% were located elsewhere or in multiple subcellular compartments. 
Interestingly, ∼42% of the peptides exhibiting differential cysteine oxidation were 
reduced, suggesting that the changes are representative of true redox regulation 
with increases and decreases in oxidation. When multiple cysteine-containing 
peptides from the same protein exhibited a total available thiols ratio near 1, 
unaltered protein expression was assumed. An increase in free and reducible 
thiols (ratio 128/126>1) likely indicates an increase in expression. Alternatively, 
diet-induced shifts in structure or local microenvironments may have altered 
accessibility or reactivity of cysteines. In cases where the ratio decreased, we 
presume that irreversible oxidation may have blocked thiols from being tagged. 
Considering such effects, our observations provide more comprehensive insight 
into the cysteine redox landscape. 
Mitochondria are highly abundant in the heart due to the normally high energy 
demand of the constantly contracting and relaxing myocardium. The majority of 
mitochondrial proteins differentially modified by HFHS diet consumption are 
involved in fatty acid metabolism, the tricarboxylic acid (TCA) cycle, and the 
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mitochondrial electron transport chain (ETC). Many contain critical cysteine 
residues that are sensitive to oxidative stress and are likely key sites for redox-
regulated protein function and metabolic adaptation.  
The most dramatic changes occurred on novel cysteine oxidation sites in well-
known proteins, such as Cys202 of citrate synthase, where oxidation increased 
from 3.7 (control) to 22.0% (HFHS). This increase translates to a 5.9-fold change in 
oxidation. Similar to results reported for a quantitative proteomic study on the 
occupancy of protein phosphorylation sites, our data show that the majority of 
changes in reversible cysteine thiol oxidation occur at occupancies ≤ 20% (Figure 
6 and ref (Wu et al., 2011)). It is conceivable that significant alterations in a small 
proportion of a protein could provide the impetus needed for dramatic 
downstream metabolic effects. With HFHS diet, the observed site occupancy 
changes were mostly positive, consistent with the hypothesis that increased 
oxidant production associated with metabolic disease increases reversible cysteine 
oxidation. The functional consequences introduced by each unique modification, 
however, remain to be determined. Dynamic oxidative modifications may initially 
increase specific protein activities to compensate for increased substrate 
availability. As overfeeding and excessive stimulation of  
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Figure 6. Distribution of peptides as a function of percentage cysteine site occupancy. 
Overall, the majority of peptides from control and HFHS diet groups exhibited a site 
occupancy of <20%. Peptides from HFHS-treated mice trend toward increased cysteine 
site occupancy compared with the same group of peptides measured in control mice. 
Reversible cysteine oxidation in 112 peptides was quantified for both control and HFHS 
diet conditions.  
metabolic pathways persist, maladaptive changes in molecular metabolism may 
contribute to metabolic dysfunction and remodeling seen in cardiac disease. 
Long-chain fatty acid activation, transport, and β-oxidation 
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Fatty acids are the preferred energy source for the heart. Interestingly, HFHS diet 
reduced multiple enzymes involved in transport of long-chain fatty acids and in 
β-oxidation (Figure 7 and Table 9). Utilization of long-chain fatty acids (>C8) 
requires ATP-dependent activation by long-chain fatty acid coenzyme A (CoA) 
ligase 1 (Acsl1) before they can be transported into mitochondria for β-oxidation. 
Acsl1 was less oxidized at Cys242. Potentially diminishing mitochondrial fatty 
acid import, 2 cysteines in the outer membrane carnitine O-palmitoyltransferase 1 
(Cpt1) were reduced (−1.6- and −1.8-fold). A previous study demonstrated that 
reversible oxidation of cardiac Cpt1b by peroxynitrite actually increases activity 
(Paulus and van Ballegoij, 2010). Once long-chain fatty acids are in the matrix, β-
oxidation splits long acyl chains into smaller acetyl-substituted molecules for use 
in the TCA cycle. Reversible oxidation was also decreased in hydroxyacyl-CoA 
dehydrogenase, which catalyzes the third step of β-oxidation. Decreases in 
reversible oxidation may arise because proteins need to be fully reduced and 
unfolded to be imported into the mitochondria. Import and/or refolding of 
mitochondrial proteins could be dysfunctional under HFHS conditions, causing a 
backup of reduced proteins. Finally, short/branched chain-specific acyl-CoA 
dehydrogenase exhibited a 2.7-fold increase in oxidation at one of its cysteines. 
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Together, these data support the hypothesis that HFHS-diet-fed mouse heart 
cannot effectively utilize its preferred substrates. 
Perturbations in glycolysis and the TCA cycle 
β-Oxidation and glycolysis are the major pathways providing acetyl-CoA for the 
TCA cycle. Multiple enzymes in glycolysis were oxidized differentially in mice fed 
an HFHS diet, including insulin-responsive hexokinase-2 (2.3-fold), which 
catalyzes the first step in glycolysis and is controlled by negative feedback. The  
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Figure 7. Decreased reversible oxidation of enzymes involved in fatty acid utilization. 
The fatty acid activation and oxidation pathways represented were generated with the 
assistance of Ingenuity Pathway Analysis Software. Increasing intensity of green indicates 
a 1.5-fold or greater decrease in reversible oxidation by HFHS diet at the highest fold-
change cysteine in any particular protein. Proteins that were detected but did not 
significantly change due to HFHS diet are white (grey fill). Legend: open arrowhead, 
translocates to; solid arrowhead, reaction; diamond head, enzyme catalysis; open circle, 
leads to. Abbreviations: Acsl1, Long-chain- fatty-acid-CoA ligase 1; CACT, 
carnitine/acylcarnitine carrier protein; Cpt1/2, carnitine palmitoyltransferase 1/2; Hadh, 
hydroxyacyl-coenzyme A dehydrogenase. 
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cysteine oxidation states of phosphoglycerate mutase 2 (−5-fold), pyruvate kinase 
isozymes M1 and M2 (−3.3 and −1.7-fold), and triosphosphate isomerase (1.7-fold) 
were also modified. Further, multiple enzymes of the TCA cycle were considerably 
altered (Figure 8 A and Table 9). Aconitate hydratase (ACO2) activity, which is 
inhibited by oxidation of cysteines in its iron-sulfur cluster, serves as a marker for 
mitochondrial reactive oxygen species (ROS) (Gardner and Fridovich, 1992). One 
cysteine in this enzyme exhibited a 4-fold increase in oxidation. 2-Oxoglutarate 
dehydrogenase, a key enzyme controlled by metabolic feedback, contained 
cysteines differentially affected by HFHS diet, with oxidation at Cys283 (1.6-fold) 
and Cys331 (9.8-fold) in addition to reduction at Cys487 (−2.5-fold). These 
modifications may affect TCA cycle turnover and the mitochondrial NAD+/NADH 
conversion that feeds electrons into mitochondrial ETC. Disturbances in TCA cycle 
metabolites and NAD+/NADH ratios are commonly observed phenomena in 
metabolic syndrome (Des Rosiers et al., 2011). The heart contains minimal 
amounts of TCA metabolites, and perturbations may reduce the capacity or even 
interrupt the cycle. Constant supply with acetyl-CoA is needed to compensate for 
efflux of metabolites required for oxidative phosphorylation, anabolic processes 
including heme biosynthesis and metabolite export into the cytosol. Replenishing 
 58 
 
a metabolic pathway with intermediates is termed anaplerosis, and fueling the 
failing heart with intermediates is a potential mechanism for sustaining energy 
metabolism (Des Rosiers et al., 2011). Nevertheless, perturbations in metabolism 
also activate other compensatory pathways. For example, increased NAD+ levels 
can also activate the poly-(ADP-ribose)-polymerase (PARP) enzymes or SirT1, 
which may cause epigenetic alterations and are known to contribute to the 
pathophysiology of diabetes.  
Mitochondrial dysfunction and impairment of the ETC 
NADH and FADH2 generated from β-oxidation and the TCA cycle provide 
substrates to the ETC for production of ATP. Various components of the ETC were 
oxidatively modified (Figure 8 B and Table 9) These cysteines may be close to 
metal binding sites or may represent very reactive cysteines with low pKa values. 
Oxidation of Cys125 in NADH dehydrogenase (ubiquinone) flavoprotein 1 
(component of complex I; 2.4-fold) confirmed a previously identified redox-
sensitive cysteine (Kumar et al., 2013). Cysteines from other subunits of complex I 
also showed oxidative changes, for example Cys194 of NADH dehydrogenase  
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Figure 8. Ingenuity Pathway analysis of the 98 proteins that showed significant 
changes in oxidation levels with HFHS diet. 
“Tricarboxylic acid cycle II eukaryotic” (p = 2.11E-13) and “Mitochondrial Dysfunction” 
(p = 3.06E-11) ranked as the top two canonical pathways. Increasing red intensity 
indicates a 1.5-fold increase or greater in reversible oxidation by HFHS diet at the 
highest fold-change cysteine in a particular protein. Increasing green intensity indicates 
a decrease in reversible oxidation by 1.5-fold or greater under HFHS diet. Grey fill 
proteins were detected, but did not significantly change due to HFHS diet. (A) 
Differentially oxidized proteins in the tricarboxylic acid (TCA) cycle. (B) Oxidative 
changes in the Electron Transport Chain, extracted from the IPA “Mitochondrial 
Dysfunction” pathway. All proteins presented in complex 1 are Nduf components. 
Legend: open arrowhead, translocates to; solid arrowhead, reaction; Diamond Head, 
enzyme catalysis; open circle, leads to. Abbreviations: Atp5h, ATP synthase subunit d, 
mitochondrial; Cox6b1, cytochrome c oxidase subunit 6B1; Cyc1, cytochrome c1, heme 
protein, mitochondrial; NDUF, NADH dehydrogenase (ubiquinone); Sdha-c, succinate 
dehydrogenase; Uqcrc/h, ubiquinol cytochrome c reductase core/hinge. 
 
 (ubiquinone) iron-sulfur protein 7 (−2.5-fold). We detected oxidative changes in 
all complexes except ATP synthase.  
Mitochondrial NADPH and glutathione levels 
Heart mitochondria contain 2 major sources for NADPH: nicotinamide nucleotide 
transhydrogenase (Nnt) and the NADPH-dependent isoform of isocitrate 
dehydrogenase (Idh2). In myocytes, the NADPH/NADP+ ratio is relatively high 
(>50; ref. (Benderdour et al., 2003)). NADPH is essential for anabolic processes and 
is also a reducing equivalent for GSH reductase, an enzyme that helps maintain 
the mitochondrial redox state by reducing oxidized glutathione (GSSG to GSH). 
Glutathione peroxidase requires GSH to detoxify hydrogen peroxide arising from 
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ETC-derived superoxide and manganese superoxide dismutase 2 (SOD2). The 
observed increase in cysteine oxidation of Idh2 from 4.7 to 10.8% site occupancy 
may decrease Idh2 activity and thus increase mitochondria-derived oxidative 
stress. Impaired function of Idh2 may be particularly problematic in the B6J 
substrain of C57BL/6 mice used in this study, as they have a mutation that renders 
them Nnt null, which increases the propensity to develop diet-induced obesity 
and insulin resistance (Nicholson et al., 2010). Freeman et al.(2006) determined in 
this common mouse model of metabolic disease that glucose intolerance, 
particularly defects in ATP-dependent insulin secretion from β cells, arises from 
decreased mitochondrial ATP synthesis. Thus, compromised antioxidant systems 
in the matrix may contribute to the increased reversible oxidation seen in 
mitochondrial proteins with HFHS diet.  
Limitations 
Although this new approach allows faster and better quantification of total 
available cysteine thiols and their site occupancy, certain technical and biological 
limitations apply. Particularly, low-abundance peptide ions can still be identified, 
but quantification by MS/MS becomes technically challenging and less accurate. 
Furthermore, alkyl halides such as IAM exhibit a more complex chemistry than 
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commonly stated. At higher pH, these compounds have the potential to modify 
primary amines and histidines. At high concentrations used for blocking, they can 
also react with sulfenic and sulfinic acid (Conte and Carroll, 2013; Jeong et al., 2011; 
Reisz et al., 2013), which would preclude downstream iodoTMT labeling of 
sulfenic acids. However, a recent study demonstrated that TCEP partially reverses 
this effect (Reisz et al., 2013). Also, sulfenic acid and S-nitrosylation are very labile 
modifications, which may anyway decompose during sample processing. On the 
contrary, complex protein structures and neighboring amino acids may stabilize 
such modifications, allowing for their quantification. For the same reason, the 
protein structure may also obstruct tagging with iodoTMT, which has been 
observed for iodoacetamide and iodoacetic acid. Nevertheless, this new 
technology enables global discovery of novel regulatory cysteine residues to guide 
functional validation in biological settings.  
Conclusions 
Our proteomics screen of global reversible cysteine thiol oxidation suggests that 
specific groups of proteins are preferentially affected by reversible cysteine 
modifications that may perturb glycolysis, β-oxidation, the TCA cycle, and the 
mitochondrial ETC. We postulate that cardiomyocytes may lose the ability to 
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utilize preferred, highly energetic fat for oxidative ATP synthesis. The impairment 
of energy supply may be triggered by enhanced radical formation, which increases 
reversible cysteine oxidation of matrix-exposed proteins, thereby disrupting TCA 
cycle and ETC pathways. Ultimately, these changes in metabolic function may be 
maladaptive, leading to a situation in which substrate supplied to the heart for 
energy generation is adequate in amount but cannot be fully utilized—a Tantalus 
paradox. This model offers specific molecular insights regarding the cellular and 
physiological mechanisms that lead to metabolic heart disease. 
Interrogating the pathophysiological relevance of oxidative changes 
Sustaining the constantly beating heart requires high levels of free energy. 
Contraction and relaxation relies on well-regulated calcium handling, which is 
especially sensitive to ATP fluxes. For example, the myocardium depends on 
Serca2a to orchestrate relaxation, a protein which requires ATP to move Ca2+ back 
into the SER against an enormous concentration gradient (Kammermeier, 1987; 
Tian et al., 1998). To meet such high energy demands, the heart utilizes fatty acid 
oxidation and oxidative phosphorylation for rapid ATP synthesis (Lopaschuk et 
al., 2010), which is why we directed our attention to oxidative changes we 
observed in the electron transport chain (ETC). Furthermore, assessing the 
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contribution of Complex I and II (CI or II) dysfunction to ATP production is simple, 
as only a single substrate and inhibitor is required for each and all of these are 
readily available. Also, CII would be an ideal complex to study because it is 
nuclear-encoded, making mutation experiments straight-forward. Finally, it has 
also been shown recently that, while ROS is commonly known to arise from CI 
and CIII, CII also produces ROS, especially when palmitate is the incoming 
substrate (Perevoshchikova et al., 2013)—matching well with this model of high 
fat diet feeding. 
As a brief review, the ETC can be energized at CI or II by pyruvate, which enters 
the mitochondria, powering the tricarboxylic acid cycle, and producing reducing 
equivalents NADH and FADH2 for CI and II action, respectively. As each of these 
and the remaining complexes transfer electrons stripped from NADH and FADH2, 
CI, III, and IV pump protons from the matrix into the intermembrane space, 
creating a proton gradient. Finally, the proton-motive force drives ATP synthesis 
as protons flow back into the matrix through ATP synthase. CI-driven ATP 
synthesis can be assessed by feeding isolated mitochondria pyruvate while 
inhibiting CII activity with malate. Succinate is an intermediate in the TCA cycle 
that is oxidized by CII (succinate dehydrogenase), producing fumarate and 
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FADH2. FADH2 is then reduced by CII as it passes along its electrons to ubiquinone, 
forming ubiquinol. We can assess the contribution of CII function to changes in 
energy production by feeding the isolated mitochondria succinate and rotenone 
(an inhibitor of CI).  
Firstly, our collaborators in the Colucci lab isolated mitochondria from hearts of 
both chow and HFHS-fed mice and measured ATP production using a luciferase-
coupled assay (Roche, Indianapolis, In). After eight months on diet, mitochondria 
from HFHS-fed mice produced less ATP than chow-fed, whether using 
pyruvate/malate or succinate/rotenone (CI and II substrates and opposite 
inhibitors, respectively). To determine the role of reversible oxidative 
modifications in decreasing ATP output, Aaron Sverdlov added the membrane-
permeable reductant dithiothreitol (DTT) to the assay. Particularly for CII-driven 
synthesis, reduction significantly restored ATP production (Figure 9 B and ref 
(Sverdlov et al., 2014)). This provided evidence of a pathophysiological role for the 
HFHS-induced reversible oxidative PTMs we observed in the heart. 
Perhaps even more exciting were the results after only four months of feeding. For 
these measurements, CII activity was assessed directly using an ELISA-based  
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Figure 9. After 8 months on HFHS diet, reduction significantly restores CII-driven (B) 
but not CI-driven (A) ATP production. 
ATP production by mitochondria isolated from C57Bl6J mice fed chow or HFHS diet was 
assessed using a luciferase-coupled assay (Roche). Supplying pyruvate and malate to 
mitochondria feeds CI- and blocks CII-driven ATP synthesis. Supplying succinate and 
rotenone feeds CII- and blocks CI-driven ATP synthesis. HFHS feeding decreased ATP 
output by cardiac mitochondria. Adding the reducing agent DTT to remove reversible 
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oxidation from thiols only restored CII-driven ATP synthesis. CD stands for control diet. 
Error bars represent SEM.  
 
kit (Abcam, Cambridge, Ma). A microplate with wells coated by a monoclonal 
antibody against CII was used to immunoprecipitate the enzyme from heart 
lysates. If CII was active, it catalyzed the transfer of electrons, producing ubiquinol. 
Ubiquinol, in turn, reduced a blue dye DCPIP (2,6-diclorophenolindophenol), 
rendering it colorless. This loss of color was measured at 600nm. As expected, 
mouse cardiac CII activity was impaired after 8 months of HFHS feeding, and 
upon addition of DTT, its activity could be partially restored. However, if mice 
were fed HFHS diet for only four months, DTT fully restored CII activity (Figure 
10 and ref (Sverdlov et al., 2016))! This aligns perfectly with the chronic oxidative 
stress and disease hypothesis: in the initial stages of disease, oxidative 
modifications are reversible, taking the form of sulfenylation, nitrosylation, and 
glutathionylation, leading to temporary, potentially adaptive changes. However, 
as disease and redox imbalance progresses, modifications turn irreversible and 
tissue damage occurs. The reversibility of these functionally relevant changes 
suggests great potential for therapeutic intervention. 
 69 
 
 
 
Figure 10. Reduction can completely restore mouse cardiac CII activity after 4 months 
and only partially after 8 months HFHS diet-feeding 
Mouse cardiac CII activity is significantly impaired after HFHS-diet feeding (B) Its activity 
can be fully restored by in vitro reduction if derived from mice fed HFHS-diet for 4 
months. (A) If mice are fed HFHS-diet for 8 months, CII activity can only be partially 
restored. CII activity was assayed using an ELISA-based kit from Abcam and is 
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represented here as mOD per minute per mg protein. CD stands for control diet. Error 
bars represent SEM. 
 
To determine if the particular cysteines that we saw oxidized in our proteomics 
screen were responsible for this change in activity, the Colucci lab later created 
redox-resistant cysteine-to-serine mutants for residues 100, 103, and 115 in subunit 
B of CII (SDHB). It is very difficult to transfect short-lived cultured primary adult 
mouse cardiomyocytes, so HEK293T cells were used as a model system. DTT-
reversible changes in CII activity observed under HFHS-feeding could be 
recapitulated by treating cells with 500uM of the oxidant hydrogen peroxide 
(H2O2). To more closely mimic HFHS-feeding, cells were treated with a mixture of 
high palmitate and high glucose, which also reversibly inhibited CII activity. 
Transfection of SDHB C100S or C103S abrogated oxidation-induced loss in activity, 
whereas C115S did not (Figure 11). Thus, of the three SDHB cysteines oxidized in 
our proteomics data, 100 and 103 appear to mediate energetic dysfunction in 
cardiac mitochondria. These two cysteines help coordinate the 2Fe-2S iron-sulfur 
cluster within SDHB; it is likely that oxidative modifications disrupt electron 
shuttling, just as has been shown for germ-line mutations to the human homolog 
of C103 (C101) in cancer patients (Bayley et al., 2005; Kim et al., 2015). One 
remaining uncertainty is the contribution of upstream proteins that  
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Figure 11. Oxidation of succinate dehydrogenase B (SDHB) Cys100 and Cys103 
inhibits mitochondrial complex II activity. 
Exposure of cells to high-glucose/high-palmitate (HGHP) media (14 hours) decreased 
CII activity in HEK 293T cells. SDHB in which Cys100Ser (C100S), Cys103Ser (C103S), 
or Cys115Ser (C115S) was mutated to a redox-insensitive serine was expressed in HEK 
293T cells, and CII activity was measured after exposure to HGHP media. (A) HGHP 
treatment decreased complex II activity in HEK cells transfected with empty vector 
(CTRL), and activity was restored after incubation of cell lysate with dithiothreitol 
(DTT; 5 mmol/L). (B) Expression of the SDHB C100S mutant prevents the HGHP-
mediated decrease in CII activity. (C) Expression of the SDHB C103S mutant prevents 
the HGHP-mediated decrease in complex II activity. (D) Expression of the SDHB C115S 
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mutant has no effect on the HGHP-mediated decrease in CII activity. Values are 
mean±SEM; n=3 to 4; *P<0.05 vs CTRL; #P<0.05 vs CTRL+HGHP; ##P<0.01 vs 
CTRL+HGHP. Figure and caption from: Aaron L. Sverdlov et al. J Am Heart Assoc 
2016;5:e002555 
 
catalyze steps in the TCA cycle, beta oxidation, or transport of substrates into the 
mitochondria. Investigating the role of upstream factors would be a worthwhile 
future direction for this work. 
It is important to note that the change in thiol occupancy for cysteines studied in 
CII were just under the 1.5-fold change cutoff that we applied to our original 
HFHS-fed mouse TMT discovery analysis. Western Blotting later confirmed that 
CII expression did not change with HFHS-diet, so changes in total available thiols 
measurements were likely due to irreversible oxidation. Thus, for the purposes of 
CII-specific examination, we only compared the reversibly oxidized thiols portion. 
This updated analysis increased the apparent change in reversible oxidation for 
these cysteines. 
Quantifying changes in percent oxidation induced by H2O2 in MetS and 
assessing method reproducibility 
The aims of our next experiment were 2-fold: 
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Aim 1: Assess variability of the method with a tagging strategy designed to 
quantify percent reversible oxidation in 4 mouse groups with n=5 biological 
replicates. 
Aim 2: To determine changes that drive development of metabolic cardiovascular 
disease, we will identify protein cysteines specifically oxidized by excess H2O2 that 
is produced in the myocardium under HFHS-feeding.  
Our collaborators in the Colucci lab previously showed that overexpression of 
catalase, the primary detoxifier of H2O2, could largely prevent HFHS-diet induced 
diastolic dysfunction (Sverdlov et al., 2016). Thus, excess H2O2 in MetS likely 
causes oxidative modifications in cardiac muscle that mediate the diet’s negative 
effects. To identify the targets of H2O2, we aimed to quantify changes in percent 
oxidation of cysteine thiols in the cardiac proteome of these mice using our iodo-
TMT-based switch technique and MS. Furthermore, we wanted to determine how 
reproducible our measurements are using this robust sample set of five biological 
replicates for each of four groups: Cat Tg vs WT, with and without HFHS-diet 
feeding for 8 months. 
This second study revealed an important weakness in our iodoTMT switch 
protocol used to quantify percent oxidation. The dynamic range between signals 
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from reporter ions for the reversibly oxidized portion of cysteines and total 
available cysteine thiols was too great to allow reliable quantification of both at 
the same time. Variability of the comparatively low signal from reversibly 
oxidized thiols was significantly greater than that of total thiols, preventing 
calculation of percent oxidation for many peptides. Biological variability between 
five different mice for different genotypes on special diet compounded this error, 
making it especially difficult to derive useful information from the HFHS-fed 
groups. In the following sections, I will discuss: 1) the tagging strategy we used to 
assess 40 different samples with the available 6-plex iodo-TMT sets; 2) our 
methods for calculating variation; and 3) general findings from comparisons of 
chow-fed Cat Tg and WT mice using data that met maximum variability cutoffs. 
Comparing percent oxidation for all four groups would require an 8-plex set. With 
only six tags, we would have to rotate between groups. While each comparison 
was important, our primary hypothesis was that the oxidative environment in Cat 
Tg mice on HFHS should mimic that of WT mice on chow diet, as they are 
protected from HFHS-induced dysfunction. Thus, we decided to repeat these two 
groups in every set and use the third pair of tags to trade between the two 
remaining groups. With five biological replicates and the ability to only compare 
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Cat Tg mice fed chow or WT mice fed HFHS diet in each 6-plex run, the required 
number of multiplex sets and MS runs doubled to 10 (see Table 8). This proved 
advantageous as it provided technical replicates for assessing reproducibility of 
the method in addition to internal controls for making comparisons between the 
alternating groups. 
Chunxiang Yao led the data analysis effort. She determined that with the amount 
of data generated from 10 runs with both biological and technical replicates, she 
would rely on the PD-generated ratios rather than calculate sums of raw reporter 
ion values. Also, each peptide considered unique by PD, even if the difference was 
only due to +/- methionine oxidation or a missed cleavage, was included.  
The inability to determine whether a missing signal is just that or should actually 
be counted as “zero” oxidation is a serious limitation. In a mouse model 
overexpressing an antioxidant enzyme, we would expect that oxidation of many 
sites may be significantly decreased or even completely prevented. This would 
limit the number of “quantifiable” peptides, as the reversible portion is lost to the 
noise. Thus, for this set we compared total available thiols to one another between 
groups in order to extract indirect information about the mice. We hypothesized 
that if total available thiols increased in the Cat Tg, it is likely that  
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the WT animal had irreversibly oxidized thiols that could not be counted toward 
total thiols. These same sites were protected from irreversible oxidation in the Cat 
Tg and could be labeled increasing the total available thiols signal.   
Table 7. Tagging strategy for  Chow and HFHS-fed WT and CatTg mice with 5 
biological replicates for each group. 
 
Chow-fed WT and HFHS-fed CatTg total available thiols (TCEP) and reversibly oxidized 
thiols (IAM) were repeated in run A and B for each biological replicate. *Chow-fed WT 
heart tissue from biological replicate #4 was used for #5 due to loss of original #5 Chow-
fed WT sample. 
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With help from statistician Xiaoyan Yin at the Framingham Heart Study, we 
determined that calculating the coefficient of variation (CV, ratio of standard 
deviation to the mean, converted to percent) would be the best method for 
assessing reproducibility between replicates. Two different ratios were calculated 
and compared: total available thiols, which consistently had higher signals for all 
animals, and percent oxidation, which incorporated low signals from reversible 
oxidation. Upon preparing a frequency distribution for the CVs of all quantifiable 
peptides, it was clear that measurements of reversible oxidation (Figure 12) were 
significantly more variable than those of total available thiols (Figure 13). It is 
important to note that because the five mouse replicates were examined across 
separate MS runs, both biological and technical variation contributed to these 
findings. Figure 13 demonstrates that the peak of variation for total available thiols 
is less than 35% for all groups, whereas variation for percent oxidation spreads 
across the entire x-axis. 
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Figure 12. Frequency distribution (histogram) of %CVs for thiol occupancy of 
reversible oxidation in the Cat Tg cohort on diet. 
Ratios of TMT tags were prepared for the following four comparisons of thiol occupancy: 
HFHS and Chow diet-fed WT mice (black circle) and CatTg mice (blue square); Cat Tg 
and WT mice fed Chow diet (red triangle) and HFHS diet (green triangle). CVs derived 
from biological replicates of ratios comparing thiol occupancy of reversible oxidation 
were widely spread, with a peak at greater than 40%. These ratios varied much more 
among the replicates than those comparing total available thiols. 
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Figure 13. Frequency distribution (histogram) of %CVs for total available thiol 
quantification in the Cat Tg cohort on diet. 
Ratios of TMT tags were prepared for the following four comparisons of total available 
thiols: HFHS and Chow diet-fed WT mice (black circle) and CatTg mice (blue square); 
Cat Tg and WT mice fed Chow diet (red triangle) and HFHS diet (green triangle). The 
majority of CVs derived from biological replicates of ratios comparing total available 
thiols were below 30%. 
 
According to the frequency distribution we decided to use a cutoff of 35% CV. 
Figure 14 provides a summary of the peptides quantified in the study that met this 
cutoff. HFHS diet added so much variability that we excluded these mice from our 
final analysis. 
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Figure 14. Overlap of Cat Tg cohort-derived TMT-tagged peptides exhibiting changes 
in total available and reversibly oxidized thiols with CV ≤35% 
Quantitative proteome analysis requires stepwise selection of qualifying MS data. In 
general, reporter ions for total available cysteine thiols (m/z 127 or 129) were more 
abundant than those for reversibly oxidized cysteine thiols (m/z 126 or 128), resulting in 
better MS quantification and lower data variability as determined by the CV. By selecting 
a cutoff CV of ≤35% for all reporter ion ratios, adequate analytical precision was attained. 
A total of 658 peptides with quantification values for total available thiols and 285 
peptides with quantification values for reversibly oxidized thiols qualified for further 
analysis. The union of both data sets contained 199 overlapping peptides, of which 109 
peptides from 82 proteins exhibited ≥1.3-fold change in reversible cysteine oxidation. 
These 82 proteins were submitted for biological pathway analysis. Chunxiang Yao et al. 
PLoS ONE 10(12): e0144025. 
 
To compare global changes in the thiol landscape of Cat Tg mice to WT mice, we 
examined total available cysteine thiols, percent oxidation, and reversible 
oxidation-only ratios of Cat Tg to WT and prepared a log2 transformed frequency 
histogram. In accordance with our hypothesis, Cat Tg mice appear to be protected 
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from baseline levels of irreversible oxidation occurring in 10 month old WT mice, 
as total thiols increased (see Figure 15 A). Both reversible oxidation and percent 
oxidation (“Reversible Cys Occupancy”) were also decreased globally in the Cat 
Tg, as indicated by the leftward shift (Figure 15 B & C). Using a systems biology 
approach to look at the proteins whose thiols were protected from oxidation in Cat 
Tg, or conversely, potentially irreversibly oxidized in the WT mice, some general 
conclusions could be drawn about the pathways potentially involved in hydrogen 
peroxide-mediated signaling in the myocardium. Briefly, with Ingenuity Pathway 
Analysis, we identified two major networks that may be preserved by Cat 
overexpression. The central nodes for these networks were p53 and the Ubiquitin-
Proteasome System (UPS). Because the heart is a post-mitotic tissue, p53 signaling 
likely perpetuates the aging process rather than tumorigenesis. Differential 
oxidation of the proteins involved in apoptotic pathways within Cat Tg mice may 
contribute to improved survival (Hasty and Christy, 2013). As for the UPS, 
preventing buildup of oxidized and misfolded proteins is critical to preventing 
cardiac aging. If this process is disrupted, aggregates can cause cellular toxicity or 
can bind and decrease  
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Figure 15. Global changes in cysteine oxidation associated with catalase 
overexpression. 
Log2 transformed reporter ion rations from Cat Tg vs. WT mice were used to generate 
frequency histograms of TMT-tagged peptides. The ratios used are as follows: (A) changes 
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in the total available thiols; (B) changes in the reversibly oxidized thiols; (C) changes in 
the thiol occupancy of reversible oxidation (dashed line indicates no change with log2 
ratio = 0). Chunxiang Yao et al. PLoS ONE 10(12): e0144025. 
 
function of important proteins. One example of a protein that could be involved 
in preventing aggregate formation is the β isoform of the chaperone Heat Shock 
Protein 105 (Hsp105 of the Hsp70 superfamily), which was significantly less 
oxidized in Cat Tg mice (Wakatsuki and Hatayama, 1998; Willis and Patterson, 
2010). Possibly, less oxidation of this protein protects its function or increases its 
activity. For further discussion of the proteins affected in Cat Tg mice, please 
consult reference (Yao et al., 2015). 
Addressing highly variable reversible signals 
To address the disparity in data quality between total available thiols and 
reversibly oxidized thiols, we needed to equalize the signals from each portion. 
Our method uniquely enables the needed adjustment, whereas other 
contemporary methods used to quantify percent oxidation do not. Rather than 
labeling free thiols with one tag, then reversibly oxidized thiols with another tag 
and calculating a percent from two tags on the same protein (Murray et al., 2012), 
the reversible portion and total portions are from two entirely separate labeled 
homogenates. Thus, if we could approximate the global ratio of reversibly 
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oxidized thiols to total available thiols, we could adjust accordingly the amount of 
protein from each portion that is added to the 6-plex set. This would bring both 
signals closer to one another in each spectrum, enabling more reliable quantitation 
of reversible and percent oxidation. To measure this ratio we used Ellman’s 
reagent, and in so doing, unveiled many steps in the switch protocol that needed 
optimization. 
Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB, MW 396.3) (Collier, 
1973; Ellman, 1959) is a symmetric compound used to quantify the molarity of free 
and protein-based thiols in a sample. It contains a disulfide that, upon 
stoichiometrically reacting with thiols, releases one half of DTNB as a visibly 
yellow reporter (TNB-), measurable at 410nm. The sensitivity of Ellman’s reagent 
is low (30uM-1mM) relative to newer, more expensive reagents including cysteine-
reactive fluorometric probes and commercially available thiol assays (i.e. Abam 
ab112158, Cambridge, Ma). However, DTNB is well-published, inexpensive, and 
simple to use, requiring only a spectrophotometer rather than a 
fluorospectrometer or HPLC equipment.  
The molar absorptivity (e) of TNB- depends on buffer components. Furthermore, 
reported e values vary. To completely unfold all proteins and make thiols 
 85 
 
accessible, I used multiple detergents (both NP40 and SDS) in 10mM Tris-8 plus 
1mM EDTA. While Beer’s law could be used to convert absorbance at 412nm to 
concentration with the correct e, we alternatively prepared a standard curve with 
dithiothreitol, cysteine hydrochloride, or reduced glutathione in buffers specific to 
my application.  
To measure the reversibly oxidized portion of protein cysteines, free thiols were 
locked down with either IAM or NEM during homogenization of heart tissue. To 
measure varying levels of oxidation, different animal models as well as in vitro 
oxidizing treatments were used. Prior to reduction of reversibly oxidized thiols 
and reaction with DTNB, excess alkylating agent needed to be removed to prevent 
alkylation of newly free thiols. Finally, after reduction of the blocked sample, 
DTNB could be added to react with thiols that were once endogenously oxidized. 
In parallel, half of each sample was homogenized with TCEP to completely reduce 
all available thiols and reacted with DTNB. Reducing agent reacts with DTNB just 
as thiols do, which is why they can be used to create a standard curve. Thus, all 
reducing agents used during the switch procedure also needed to be removed 
prior to measuring the molarity of thiols with DTNB. 
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One of the first tests aimed to compare basal, artificially-oxidized, and total 
available protein thiols from a mouse left ventricle. To artificially increase 
reversible thiol oxidation, homogenate was treated with 10mM GSH/GSSG 
mixture (70:30) for 20 minutes at RT followed by alkylation of remaining free thiols. 
A 3x buffer-equilibrated gel filtration column with 7kDa molecular weight cutoff 
(Zeba™ Spin desalting columns, Thermo Fisher Scientific, Waltham, Ma) was used 
to desalt both the oxidizing and alkylating reagents prior to reduction and again 
prior to adding sample to a 210uL microplate assay with final DTNB concentration 
of approximately 1mM. In repeated attempts, the GSH/GSSG treated sample 
produced signal significantly greater than basal and total available thiols, which 
is impossible (Figure 16). Since GSH can react with DTNB to produce TNB- and its 
resulting yellow color, these results indicated that the Zeba columns were not 
efficiently removing GSH/GSSG, and potentially the alkylating reagents. This 
would cause problems at each step in the switch protocol. 
TNB- assay to measure left over alkylating reagents. 
Endogenous reversible oxidation has been underestimated with this protocol if 
alkylating reagent is not being completely removed prior to the reduction step.  
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Figure 16. DTNB measurements of reversibly oxidized compared to total available 
thiols in basal and GSH/GSSG-treated heart tissue lysate. 
DTNB was used to measure basal and GSH/GSSG-treated levels of reversible oxidation 
and total available thiols in heart tissue lysate. As expected, basally oxidized thiols are 
only a portion of total available thiols (marked by dotted line at 1). GSH/GSSG-treated 
sample reacted with DTNB in such a way that it appeared reversible levels of oxidation 
were nearly 3 times that of total available thiols for the same sample, which is impossible. 
This indicated that Zeba desalting columns used to remove excess GSH prior to the assay 
were not efficiently desalting the sample. Leftover GSH reacted with DTNB, leading to an 
exaggerated measurement of reversibly oxidized thiols. 
To determine if excess alkylating agent remained, we used the TNB- assay. By 
completely reducing DTNB with an acid-labile reducing agent NaBH4, we made a 
stock solution of intensely yellow TNB- (Jeitner et al., 2013). The HPLC trace in 
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Figure 17 (courtesy of Markus Bachschmid) shows the different products of this 
reduction as well as derivatization of TNB- with IAM.  
To test the reactivity of TNB- with alkylating agent in an assay format, 40uL of a 
range of concentrations of NEM was added to 105uL of TNB- and 65uL of buffer. 
A linear decrease in yellow color correlated with increasing concentrations of 
NEM up to 1mM (Figure 18). 
An important factor affecting the accuracy of quantitation of endogenous 
reversible cysteine oxidation is how quickly free thiols can be locked down during 
homogenization of tissue. In our initial TMT-switch studies, we used IAM as the 
blocking agent because it matched the chemical reactivity of iodo-TMT tags. 
Furthermore, there was concern from preliminary MS studies in our lab showing 
heavy non-specific labeling of histidine, lysine, tyrosine, and methionine by NEM.  
I revisited this question and found in the literature that NEM is reported to be 
more efficient—rapid, complete, and specific (Rogers et al., 2006). Importantly, 
electrophiles can react with sulfenic acid forming various covalent adducts, only 
some of which are reducible. In the switch protocol, sulfenic acid modifications 
should ideally be included in measurements of reversible oxidation, but these 
species would prevent their  
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Figure 17. HPLC trace of TNB-, DTNB, and TNB-IAM. 
A) DTNB was reduced almost entirely to form the product TNB-. B) TNB- was reacted 
with IAM to form TNB-IAM, shifting the retention time of the analyte from 13.781 to 
approximately 9 minutes. 
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Figure 18. Reactivity of TNB- with NEM. 
Absorbance measured at 412nm decreased linearly at concentrations assessed between 
0.1 and 0.8 mM. A minimum yellow measurement derived by reaction of TNB- with 
50mM NEM was subtracted from all absorbances for normalization that is usually 
afforded by a “blank”. Buffer components and assay proportions are listed in the top 
left table. 
 
labeling and, in MS-based analysis, would also dilute the peptide signal by 
changing affected peptides’ m/z. It was shown that these adducts formed by NEM 
were more reducible than those formed by IAM, further supporting its use (Reisz 
et al., 2013). I used TNB- to compare the kinetics of maleimide, NEM, IAM, and 
BIAM under conditions specific to my protocol (Figure 19). I also compared these 
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reactions at various pHs, but found that the TNB--based assay functioned best at 
pH 7.4 and decently at pH 8.0, yet could not be used for assessments at other pH 
levels. At pH 7.4, NEM reacted fastest and BIAM took more than two hours to 
react fully. This study informed the length required for both of these steps in the 
switch protocol. In summation, I changed our original conditions of alkylating 
with IAM and labeling with BIAM for 1 hour each to alkylation with NEM for 20 
minutes and labeling with BIAM (or iodo-TMT) for two hours. 
With the reverse Ellman’s assay working, I was able to directly assess desalting 
efficiency. Tests confirmed that Zeba gel filtration columns were not sufficiently 
removing alkylating agents and other small molecules. To replace this step that is 
required at three points throughout the switch protocol, I needed a quick and easy, 
yet thorough method. These necessary characteristics excluded the use of size-
exclusion filtration devices (i.e. Amicon, EMD Millipore, Darmstadt, Germany, ref 
(Wisniewski et al., 2009)), which require multiple centrifugation steps of up to 40 
minutes each. Additionally, dialysis and ice-cold acetone pptn call for O/N 
incubations for maximum desalting and protein recovery. Although efficient, pptn 
with high amounts of trichloroacetic acid, as I had used previously  
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Figure 19. Kinetics of TNB- reacting with various alklating agents 
Various alkylating agents were reacted with TNB- and monitored for consumption of 
yellow color at Abs 412nm for 2 hours. Reaction conditions are listed in the table at top 
left. At pH 7.4, NEM reacted with TNB- to completion by 50 minutes, whereas BIAM was 
still reacting at 120 minutes. 
 
(Held et al., 2010), was avoided due to safety concerns. Back in 1984, Wessel and 
Flugge (1984) described “a method for quantitative recovery of protein in dilute 
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solution in the presence of detergents and lipids”, which met the desired 
conditions. The procedure involves adding four parts MeOH to one part sample, 
then one part chloroform, and three parts water, with vortex and short spins 
between each addition. The result is a chloroform separation between an aqueous 
phase containing small molecules (cloudy top layer to be discarded) and the 
organic phase containing the protein pellet. The final step is to add 3 parts MeOH, 
vortex, and then spin and discard liquid. This washes the pellet and helps remove 
the chloroform. I used TNB- to compare the desalting efficiency of 
MeOH/chloroform (M/C) pptn to Zeba columns. 15uL of a highly concentrated 
protein sample blocked with 50mM IAM then diluted to 5ug/uL (100uL) with final 
IAM concentration of 16.5mM IAM was desalted using buffer-equilibrated 7kDa 
Zeba column or M/C pptn. The latter nearly eliminated consumption of TNB- 
(Figure 20).  
However, different attempts delivered slightly varying results, so I tested whether 
extra MeOH washes of the protein pellet could solve this variation. Alkylating 
agents, including NEM and IAM, are soluble in MeOH, making this procedure 
effective. I also returned to the original problem, where GSH/GSSG was 
inefficiently removed by Zeba columns. To measure excess GSH/GSSG, pre- 
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Figure 20. Reactivity of TNB- with left over alkylating agent following desalting of 
protein samples with Zeba columns or M/C pptn. 
Samples were spiked with 50mM NEM prior to either desalting procedure. The yellow 
tinge of heart lysate changes the absorbance at 412nm, so respective sample backgrounds 
were subtracted from each. According to the slope, sample still reacts with (consumes) 
TNB- following Zeba desalting, but not following M/C pptn (flat like TNB- blank). 
 
blocked heart tissue lysate was “treated” with the small molecule oxidizing mix 
then subjected to pptn or gel filtration. Empirically, I found that a starting 
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concentration of 27.5 mM of GSH/GSSG (70:30) enabled detection of yellow color 
upon addition of column-desalted sample to the DTNB assay. Between one to two 
extra MeOH washes of the precipitated protein eliminated reactivity with DTNB, 
while Zeba-desalted sample continued to react heavily (Figure 21). 
A Coomassie gel (Imperial Protein Stain, Thermo Fisher Scientific, Waltham, Ma) 
confirmed that there was no major loss in particular protein bands, regardless of 
the work-up used (Figure 22). Upon turning to pptn for multiple steps in the 
switch, it was clear high amounts of strong detergent would be required to 
resolubilize the protein pellets. Thus, I increased the SDS concentration to 2% at 
this point. Even then, sometimes the pellet could not be entirely solubilized, but 
the subsequent hour-long TCEP reduction at 37°C helped with this issue. 
To visualize this difference in desalting efficiency and how it affects downstream 
steps, I compared the final pull-down results after using either Zeba or pptn at all 
three desalting steps (after alkylation, reduction, and labeling). A non-reducing 
blot of basal, GSH/GSSG oxidized, and totally reduced showed the expected 
pattern of increased oxidation after treatment (Figure 23). 
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Figure 21. DTNB reactivity with GSH/GSSG-treated heart lysate following desalting 
with Zeba columns or M/C pptn. 
Pre-blocked (alkylated) heart lysate “treated” with GSH/GSSG was desalted using a Zeba 
column or M/C pptn followed by 1, 2, or 3 MeOH washes of the protein pellet. The 
reactivity of these with DTNB was compared to non-desalted (“STRAIGHT”) and blank. 
Zeba-desalted sample reacted highly with DTNB, suggesting excess GSH is not being 
removed by the column. M/C nearly eliminated reactivity with DTNB, indicating pptn 
efficiently removes small molecules. 
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Figure 22. Coomassie gel assessing protein loss following different desalting 
methods. 
Protein samples assayed in Figure 21 were electrophoresed on a polyacrylamide gel and 
stained with Imperial Gel Stain (Pierce) to determine if any of the desalting methods cause 
marked protein loss. There was little to no protein loss following Zeba or Pptn (+ up to 
three MeOH washes). 
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Figure 23. Pan-GSH blot comparing protein-GSH adducts in basal and GSH/GSSG-
treated heart lysate. 
Prior to the biotin-switch, samples processed by either desalting method (Zeba or pptn) 
exhibited the expected pattern of increased glutathione adducts due to treatment with 
10mM GSH/GSSG (70:30) and elimination of signal by reduction. Heart lysates were either 
blocked immediately (preserving basal levels of GSH adducts), treated with GSH/GSSG 
to increase GSH adducts, or completely reduced to remove all reversible oxidation 
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(including GSH adducts). Following electrophoresis under non-reducing conditions and 
transfer to PVDF, membranes were blotted for GSH protein adducts. Gapdh blotting of 
BIAM-labeled input was used as a loading control. 
 
A blot comparing the supernatant after pull-down to the streptavidin bead elution 
clearly demonstrated how inefficient desalting prevents pull-down and that ppt 
by M/C was able to correct the issue (Figure 24).  
Actin has been shown to be oxidatively modified (Lassing et al., 2007) and served 
as a control here. The amount of biotin-labeled actin pulled down by beads 
increased with treatment and even further for total available thiols if ppt was used, 
whereas actin was not even detected in samples desalted with gel filtration 
columns (Figure 25).  
In troubleshooting for the first TMT study, we also found desalting to be critical 
prior to TMT pull-down. Bead capacity is low compared to the molarity of labeling 
reagent added, which needs to be in excess for efficient labeling of all thiols. Even 
if a gel filtration column is 95% efficient, which they are in my hands, the left over 
5% still swamps the beads, out-competing TMT- (or biotin-) labeled protein. 
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Figure 24. Streptavidin-bead pull-down efficiency following desalting via Zeba or 
M/C pptn. 
Inefficient desalting of excess BIAM label by Zeba 7kDa gel filtration columns prevents 
streptavidin bead pull-down of biotin-labeled proteins. M/C pptn and washing of pellet 
greatly improves pull-down efficiency. 
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Is desalting required after TCEP reduction step? 
It is always better to minimize sample handling in order to limit introduction of 
artefactual differences between samples. That is one major benefit of multiplexing 
with iodo-TMT tags—up to six samples can be combined prior to the last pptn step, 
digestion, pull-down, and clean-up. This is also why we used TCEP as a reductant 
in our earlier TMT experiments. DTT irreversibly binds cysteine-reactive labels, 
whereas TCEP should not interfere with downstream labeling. Isotope-labeled 
isobaric TMT tags are expensive and sets are sold with small quantities (0.2mg) of 
each tag, so the efficiency of that step is important. To validate that TCEP does not 
interfere, I compared the bead elution between total, basal, and basal without the 
middle desalting step (after TCEP reduction). For all conditions, I used pptn to 
clean up after alkylation and labeling. Unfortunately, the blot revealed that left-
over TCEP decreases labeling by BIAM under the optimized conditions of two 
Figure 25. Desalting with M/C pptn between each switch step improved streptavidin 
bead pull-down of biotin-labeled protein (Actin), while Zeba-desalting completely 
abrogated pull-down. 
GSH/GSSG indicates 10mM (70:30) treatment used to increase reversible oxidation, 
represented by increased signal in bead-elution. “Total” indicates total available thiols 
were labeled with BIAM and should exhibit maximum signal. Supernatant is not being 
depleted. 
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hours at RT (Figure 26). Going forward, three pptn steps would be required for an 
accurate switch. 
Improving immunoprecipitation 
In the previous experiments, it was apparent that there is still much more signal 
left in the supernatant compared to pull-down, even after thorough desalting by 
pptn. Potentially, the amount of detergent added to help solubilization of 
precipitated protein was too harsh for immunoprecipitation, despite 
streptavidin<>biotin binding being one of the strongest known natural 
interactions (Weber et al., 1989). By diluting the BIAM-labeled sample 20x with   1% 
NP40, 50mM Tris pH 8.0, and 150mM NaCl, the SDS concentration was decreased 
to 0.1%. I controlled for protein dilution in this comparison by diluting the original 
sample 20x with the same harsh buffer used for resuspension. To add another layer 
to this evaluation, I used a low and high H2O2-treated sample for each condition. 
The amount of protein in the supernatant cannot be directly  
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Figure 26. TCEP reducing agent interferes with labeling. 
This led to underestimation of reversible oxidation. “Total” indicates total available thiols 
or maximum signal. “Basal” indicates basal levels of reversible oxidation. “w/o pptn #2” 
indicates basally oxidized sample carried through the switch protocol without pptn 
between reduction and labeling step. w/o pptn #2 is consistently less labeled than basal 
sample switched with pptn after every step. Glrx Tg, WT, and KO mouse tissue was used 
for comparison. 
 
compared to the previous blot, as it has been diluted 20x. However, there was a 
dramatic increase in protein pulled-down in low detergent buffer compared to the 
harsh conditions used previously (see “Bead Elution”, Figure 27). 
In the previous pull-down attempt, I used 125uL of streptavidin magnetic beads 
(New England Biolabs, Ipswich, Ma) for 200ug of protein. Rough calculations 
using an estimated average protein mass of 50kDa and cysteines representing (a  
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Figure 27. Diluting the BIAM-labeled lysate to decrease the SDS concentration to 0.1% 
prior to streptavidin-bead precipitation increases pull-down efficiency of actin. 
However, no differences were detected between pull-down of samples treated with high 
(100uM) and low (12.5uM) H2O2 concentrations. 
 
generous) 3% of amino acids in the proteome, indicate that this volume of beads 
should have been about 4x the amount of total labeling (Figure 28). 
The absence of a detectable difference between low and high oxidizing treatments 
suggested the need for further optimization. Thus, next I tested pull-down with a 
range of protein inputs (25-200ug) (Figure 29) and bead volumes (125-500uL) 
(Figure 30).  
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Figure 28. Estimating streptavidin bead binding capacity for biotin-labeled protein 
cysteine thiols. 
Calculating pmol of cysteine thiols in 200ug of protein input and binding capacity of 
125uL NEB magnetic beads. Assumptions made include 50kDa average protein mass and 
cysteines comprise 3% of all amino acids in the mouse proteome. 
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Figure 29. Assessing bead binding capacity by varying protein input. 
25, 50, 100, and 200 ug of biotin-switched protein lysate was subjected to streptavidin-
bead pull-down (115uL beads) to determine bead capacity for labeled protein. Increasing 
signal in the bead elution following immunoblotting of Cpt1b, Actin, and Csrp3  indicated 
that  115uL of NEB streptavidin beads could bind the labeled portion of at least 100 ug of 
input protein. Artifact visible on right side of blot is due to a tear in the gel prior to transfer. 
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Figure 30. Assessing bead binding capacity by varying bead volume. 
50ug of biotin-labeled protein was subjected to pull-down by 125, 250, or 500 uL of NEB 
streptavidin beads to determine ideal bead volume per protein input. Reaching maximum 
signal between the 125 and 250 uL bead elution of basally oxidized (and labeled) samples 
following immunoblotting of Cpt1b, Actin, and Csrp3  indicated that  ≤ 250 uL of NEB 
streptavidin beads were required to bind the basally labeled portion of 50 ug of input 
protein. Pull-down efficiency of total available thiols was protein-, and potentially 
antibody/epitope-, dependent. 
 
I probed for three proteins with differing abundances: Cpt1b, Actin, and Csrp3. 
Protein pulled-down by 115uL beads increased with increasing amounts of input 
protein. If the amount of labeled protein exceeded bead capacity, signal from the 
elution should not have continued increasing.  
These results would suggest that 115uL of beads could sufficiently bind at least 
100ug of labeled protein.  
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To optimize bead quantity, I used 50ug of input protein and compared 125, 250, 
and 500uL of streptavidin beads (NEB). Each protein behaved differently.  
Actin did not increase in intensity as bead volume increased, indicating 125uL 
beads were enough for efficient pull-down of that protein. Basal Csrp3 was pulled 
down well and did not seem to increase either. The total portion was hard to 
interpret—as only actin’s total rivaled the basal oxidation pull-down; Csrp3 was 
absent. Total is intended to be labeled at all available cysteines, of which reversibly 
oxidized should only be a fraction. For Csrp3, it is clear from this and other blots 
(not shown) that complete labeling of its 16 cysteines either impedes pull-down or 
detection by the Csrp3 antibody. Interestingly, the basally oxidized portion of 
Cpt1b was more intense than total. This could be due to the same phenomenon 
seen with Csrp3, but affecting Cpt1b to a lesser degree. In summary, these findings 
suggest that pull down needs to be optimized to the targets of interest. Beads are 
a limiting factor, cost-wise. Adding enough to deplete the supernatant of all 
biotinylated proteins would be ideal, but to do so, one needs to limit the input 
protein (Figures 31 & 32). At the same time, the input needs to be large enough 
that the specific targets can be detected in the elution, which depends on 
abundance and levels of oxidation compared to all the other proteins in the 
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homogenate. Furthermore, detection is affected by sensitivity of the antibody used 
and whether labeling impedes detection of the recognized epitope. One must 
strike a balance. Considering all of these factors, I continued with 25ug protein 
input and 200uL beads (for details regarding binding capacity see Figure 28). 
 
Figure 31. Re-probing membrane from figure 29 with streptavidin-conjugated IR 
Dye 680 (Licor) to visualize overall labeling. 
With increasing protein input, more protein is left over in the supernatant. However, 
labeled protein captured by beads also increased with increasing input. Artifact visible 
on right side of blot is due to a tear in the gel prior to transfer. 
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Figure 32. Re-probing of membrane from figure 30 with streptavidin to visualize 
depletion of supernatant by varying volumes of beads. 
Biotin-labeled protein remaining in the supernatant after pull-down of total available 
thiols and basal reversibly oxidized thiols. 125, 250, or 500uL of NEB streptavidin beads 
were used to pull down 50ug of input protein. Total available thiols required more 
beads to deplete the supernatant than basally oxidized thiols, but both were clearly 
being depleted by increasing bead volume. This is a re-probing of the membrane from 
figure X.0. The beads half of the blot was blown-out in the image acquired so it is not 
included here. 
 
To test the final protocol I aimed to compare GSH/GSSG-treated heart 
homogenate to basal (endogenous), blocked or reduced up-front for reversibly 
oxidized and total available thiols, respectively.  If the procedure worked, the 
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following pattern (from least to most BIAM labeling) should be visible at both 
the labeled input level and after pull-down: basal oxidation, GSH/GSSG-treated, 
then total. To limit differences between the conditions, a single heart 
homogenate was prepared then split so that one half could be treated with 
10mM GSSG/GSH  
(70:30) while plain buffer was added to the second half. After a 25 minute room 
temp rotation of GSSG/GSH condition (or ice incubation of basal), 10 minute cold 
centrifugation at max speed, and Zeba desalting to remove bulk of GSSG/GSH 
treatment, both conditions were split again so that 50mM NEM or 10mM TCEP 
could be added for eventual labeling of reversibly oxidized or total available thiols, 
respectively. After RT (room temp) incubation, protein was precipitated and 
washed using MeOH/Chlor protocol, then all four conditions were reduced with 
10mM TCEP for 45 minutes. After another round of pptn, samples were BIAM-
labeled at RT for 2 hours. Before proceeding with clean-up and bead pull-down, 
the input was blotted for labeling pattern (Figure 33). 
The pattern was as expected, with both total conditions evenly and maximally 
labeled, basal least labeled, and treated more labeled than basal but less than total. 
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However, we were concerned about how muted the changes were. Instead of 
continuing with pull-down on this set of samples, I repeated the procedure  
 
Figure 33. Streptavidin blot of biotin-labeled input is first evidence that changing from 
Zeba to pptn between steps overall improved the biotin-switch protocol. 
Completely reduced, total available thiols samples, with and without in vitro treatment, 
exhibit equal maximum labeling. Treatment with 10mM GSH/GSSG (70:30 ratio) 
increased labeling compared to basal. The low degree of difference in labeling between 
samples was concerning, but the pattern is greatly improved. Lanes were removed 
between those displayed (indicated by vertical line). 
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with a range of H2O2 concentrations to see if we could obtain larger changes. 
Because I wanted to compare all conditions as directly as possible, these samples 
were only blocked, treated, or reduced after homogenization and it was possible 
that this elevated the baseline level of oxidation. To determine if this was the case, 
I included an extra condition. I split the heart piece in half before homogenization, 
as I would usually do for each sample during the TMT-switch. One half was 
blocked with NEM during homogenization, while the other half was treated as 
before. After homogenization, the non-blocked sample was split for different H2O2 
treatments, blocking, or total reduction. This experiment clearly demonstrated 
what scientists in the oxidation field know well: immediate blocking or reduction 
(as tissue is thawed) is absolutely critical to limit artefactual oxidation. Changes 
will be impossible to discern without these precautions (Figure 34). 
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Figure 34. Streptavidin blot showing high levels of background oxidation/labeling 
when blocking of free thiols is delayed. 
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Blocking free thiols immediately during homogenization of tissue is critical to preventing 
artifactual oxidation. If alkylating agent was not added until after homogenization and 
incubation for lysis (or H2O2 treatment of other samples, in this case), “basal” levels of 
oxidation were greatly increased, matching that of H2O2-treated samples. High levels of 
background oxidation make it impossible to distinguish differences in low levels of 
endogenous or in vitro oxidation. Actin was used as a loading control. 
 
Final switch protocol for quantifying percent oxidation 
The biotin-switch protocol, including all necessary precautions for an accurate 
assessment of endogenous reversible oxidation and total available thiols, was 
finally complete. It is as follows: 
1) Prepare homogenization buffer (HB) and add Roche complete mini protease 
inhibitor tablet, 1 per 10ml. 
a. HB: 2% SDS, 1% NP40, 150mM NaCl, 50mM Tris pH 8.0, 0.5% Na 
Deoxycholate, 100uM DTPA in ddH2O 
b. Must contain 10mM TCEP (total) or 50mM NEM (reversible) 
2) Homogenize snap frozen, perfused mouse left ventricle in 2mL screw cap tubes 
with 2mm ceramic beads using the Magnalyzer at 6000rpm for 20 sec, 3-4 times 
with ice breaks of 2-3 minutes between. 
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3) 10uL:1mg (ice cold HB: left ventricle tissue wet weight) is flexible, but maintain 
same ratio among all samples. 
4) Probe sonicate for ~15 pulses at 20% duty cycle, output 2, to sheer DNA. 
5) Centrifuge at max speed, 4°C, and move supernatant to new tube. Discard 
pellet, if any. 
Save portion for non-reducing anti-GSH blot to assess differences in glutathione 
adducts (can also be taken right before TCEP addition) 
6) Rotate at RT for 20 minute incubation to allow blocking (or initial reducing). 
7) Precipitate 1 part sample with sequential additions of 4 parts MeOH, 1 part 
chloroform, and 3 parts water, with vortexing and short spins between each 
addition. Discard top layer. Wash pellet with 4 parts MeOH two times. 
8) Resuspend protein pellet in HB containing 10mM TCEP. 
a. Can be difficult to resolubilize. Careful to not let pellet dry after removal 
of MeOH washes. It is useful to double the initial volume of HB when 
resuspending. Gentle RT (room temp) vortexing for 20 min prior to 
vigorous vortex and TCEP incubation can also help. 
9) Reduce for 45 min at 37°C with shaking. 
10) Precipitate as above. Wash only once with MeOH. 
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11) Add cysteine-reactive label (i.e. BIAM) at 3mM and incubate for 2 hours at RT 
with gentle mixing. 
12) Precipitate as above. Wash three times with MeOH. 
13) Resuspend in HB. Once solubilized, assess protein concentration. 
 Save portion for labeled input. 
14) Dilute 25ug of protein 20x with low-detergent buffer 
a. 50mM Tris pH 8.0, 1% NP40, 150mM NaCl in ddH2O. 
15) Add 200uL NEB magnetic streptavidin beads that have been washed three 
times with low-detergent buffer. 
16) Rotate sample with beads O/N at 4°C. 
17) Wash beads to remove non-specific binding with 5 minutes room temp rotation 
for each: 
a. 2 x with low-detergent buffer 
b. 2 x with PBS+150mM NaCl 
c. 1 x with PBS 
18) Elute for 5 minutes with shaking in 2.5x Laemmli buffer supplemented with β-
ME. 
19) Boil for 5-10 minutes and continue with Western blotting. 
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In the final test of this protocol, I compared a low and high oxidizing treatment to 
basal and total. In this case, I prepared homogenate in the presence of TCEP or 
NEM. For treatment, TCEP homogenate was desalted with Zeba columns then 
treated with 3.5 mM or 8 mM Diamide+GSH mix for 15 minutes at room temp. 
Diamide helps in the formation of disulfides, including mixed disulfides between 
cysteines and free GSH. After treatment, samples were blocked with 50mM NEM 
for 25 minutes. An untreated portion of TCEP-desalted homogenate was blocked 
with NEM as a negative control. The remaining steps were as described above. 
GSH-adducts reflected the treatment levels, with TECP completely removing all 
anti-glutathione signal (Figure 35 A). BIAM labeling of input was also as expected, 
with graded signal from basallowhightotal (Figure 35 B). Pull-down and 
probing for actin confirmed this pattern (Figure 36). 
“Ellman’s ratio”: molarity of reversibly oxidized thiols compared to total thiols 
Throughout the process of optimizing the switch protocol, samples were assayed 
for nmol thiols/mg protein using Ellman’s reagent. In general, approximately 80 
ug of completely reduced (total) and 500-600 ug of blocked (reversible-only) 
protein was added to a microplate assay with final volume of 210uL and 1mM 
DTNB. Heart homogenate has a yellow tinge to it which needs to be controlled  
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Figure 35. Anti-GSH and streptavidin blotting indicate reversible oxidation 
appropriately increases with oxidizing treatment. 
(A) Glutathione adducts (–GSH) on proteins, detected only in a non-reducing gel, increase 
incrementally from basal to high Diamide+GSH treatment. “Total” was completely 
reduced with TCEP and effectively eliminated –GSH signal. (B) After biotin-switch of 
heart protein with TCEP as the reductant, BIAM-labeling indicated an increase in overall 
reversible cysteine oxidation with increasing oxidizing treatment. In this reducing gel, 
“total” is fully labeled with biotin at all available cysteines and thus shows maximum 
signal. These blots were obtained with help from Maya Kim. 
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Figure 36. Biotin switch protocol reflects expected increase in reversible oxidation of 
actin with oxidizing treatment. 
 
for by subtracting a buffer+sample blank (without DTNB). Buffer alone served as 
the blank for the DTT standard curve, which ranged from 0.007813 to 0.5mM 
(0.015625 to 1mM thiol equivalent). The ratio of reversible to total thiols varied 
greatly. Part of this variation was due to the changing protocol. To determine the 
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final “Ellman’s ratio” that I would use for adjusting protein amounts added to the 
multiplex TMT set, I averaged the ratio derived from all the varied protocols with 
the ratio from one of the very last optimized switches (Figure 37). Every thiol 
behaves differently and there is a wide range in protein abundance in whole tissue 
homogenate, thus this would only be a rough estimate used to help equalize the 
signals from reversible and total portions of each sample. Ultimately, I would add 
6.6x less TCEP-treated protein than blocked when combining six iodo-TMT 
labeled samples (3 mice, each with total and reversible portions) for pptn, 
digestion, and enrichment. 
iodoTMT experiment with ratio correction 
The primary goal of the ratio-correction experiment was to assess whether the final 
optimized switch protocol and 6.6x ratio adjustment between reversible and total 
portions decreased variability among reversible signals. With the added aim of 
finding potential targets of Glrx, I compared glrx KO, Glrx WT, and Glrx TG mice 
in the iodoTMT sixplex set. Validating genotypes derived from tail snips and PCR 
with Western blotting proved difficult. After multiple failed attempts to blot for 
Glrx in left ventricle samples, I tried to blot liver and skeletal muscle, as well as 
positive and negative controls for each organ provided by two colleagues  
 123 
 
 
 
Figure 37. “Ellman’s Ratio”: molarity of reversibly oxidized thiols represented as a 
percentage of total available thiols. 
“Ellman’s Ratio” was determined by reacting DTNB with samples derived from (A) 
varied switch protocols and (B) the final optimized switch protocol. The average Ellman’s 
Ratio was 100/15, which indicated that on average, labeling in total available thiols was 
6.6 times greater than reversibly oxidized thiols. 
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in my lab (“DS” for Di Shao and “YW” for Yosuke Watanabe) (Figures 38 & 39). I 
also tested whether Glrx could be seen in red blood cell pellet or plasma, although 
did not expect those two to work. Interestingly, blots of both liver and skeletal 
muscle as well as colleagues’ controls matched the expected genotypes. 
Unfortunately, Glrx was obscured in all left ventricle samples.       
I turned to reverse transcription-qPCR as a way to directly assess glrx mRNA 
expression in the left ventricle, using ribosomal protein S18 for normalization 
(Figure 40). My positive and negative controls for mouse glrx were from YW 
skeletal muscle (Figure 40 A). For human glrx, which is overexpressed in the Glrx 
TG mouse model, negative controls were from my Glrx KO cohort, but I did not 
have a positive control. The expression level in a Glrx TG mouse was 
extraordinarily high compared to all other mice assessed for human Glrx, so we 
found this acceptable (Figure 40 B). With these methods in place, three mice with 
validated genotypes (Glrx TG, WT, and KO) were finally ready for testing the 
ratio-adjusted TMT-switch. 
Ratio-adjusted MS analysis 
The primary goal of this experiment was to determine whether the ratio-
adjustment strategy could equalize reproducibility between data from total  
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Figure 38. Western blotting of mouse skeletal muscle (SkM), liver, and plasma tissue 
from the Glrx KO cohort to verify genotype with protein expression. 
The membrane was probed for mouse Glrx (custom-made rabbit polyclonal antibody 
from Bethyl Labs). Positive and negative controls (skeletal muscle courtesy of YW) are in 
the two right-most lanes. Glrx could not be detected in plasma. Mouse designations (i.e. 
“WT 1”) indicate expected genotype according to PCR. 
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Figure 39. Western blotting of mouse left ventricle (LV) to verify genotype of Glrx KO 
cohort. 
LV samples were blocked (N) or reduced (T) for reversibly oxidized and total available 
thiols, respectively. Red blood cells (RBC) were also blotted. Positive and negative 
controls (liver courtesy of DS; LV controls not available) are in the two left-most lanes. 
The membrane was probed for human Glrx using a custom rabbit polyclonal antibody 
from Bethyl labs. hGlrx was obscured in all LV samples and could not be detected in 
plasma. Mouse designations (i.e. “WT 2”) indicate expected genotype according to PCR. 
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Figure 40.  RT-qPCR was used to verify genotypes with Taqman (Thermo) primers for 
A) mouse and B) human glrx. 
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Columns are labeled with expected genotype according to classic PCR. mRNA expression 
matched the expected genotype for all mice assayed. Positive and negative controls for 
mouse glrx were derived from SkM and courtesy of YW. Only negative controls were 
available for human glrx. 
 
available thiols and reversibly oxidized thiols. This would increase the number of 
peptides for which percent oxidation can be quantified and functional relevance 
assessed. Secondarily, we combined three different genotypes, either 
overexpressing, lacking, or normally expressing Glrx, in an effort to identify 
potential glutathione sites; however, it is important to keep in mind that these mice 
were not stressed by diet or any other treatment, so the differences would have to 
be apparent at baseline. 
To enable caclulations of percent CV, but without added biological variation, the 
entire work-up was repeated three separate times on the same hearts. The initial 
homogenization in TCEP or NEM-containing HB, up through the one hour 10mM 
TCEP reduction, was completed once on each heart at the beginning. We carried 
the samples through to reduction because we did not want to risk over-alkylation 
of non-cysteine sites during storage. After reduction, each sample was separated 
into three portions (A, B, and C) and frozen as lysates for separate handling from 
that point on. To exclude isotope effects, the tags were shuffled among the samples 
for each analytical set (Table 9). Each set was run on the  
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Table 8. Tagging scheme for ratio-adjusted MS analysis of Chow-fed Glrx mouse 
cohorts. 
 
Three analytical replicates were designated A, B, and C. Each of these were run three times 
on the Q-Exactive, with 2 and 3 each programmed with exclusion lists from 1 and 2, 
respectively; all three were combined in a MUDPIT analysis. The legend is as follows: 
“Tg” for Glrx Tg; “WT” for the mix of one WT mouse from each cohort; “KO” for Glrx 
KO; “N” for NEM-blocked (reversibly oxidized thiols); and “T” for total available thiols. 
 
UPLC-Q Exactive system three times (asterisk in Table 9) by our collaborator Mark 
McComb in the Cardiovascular Proteomics Center at BUMC, with exclusion lists 
prepared from the preceding run for each of the two latter runs. 
In the first TMT-proteomics experiment described in this dissertation, I calculated 
the sums of reporter ions prior to computing ratios. In the second experiment, C. 
Yao used PD-derived median-based ratios. In this experiment, combining all data 
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from the three sequential, complementary runs of each set prior to search and 
assignment would be ideal. MudPIT (Multidimentional Protein Identification 
Technology) scoring, which is more aggressive when considering protein 
assignments from large datasets, would help minimize false hits (Guo et al., 2008). 
However, sums should only be created from PSMs (peptide spectrum matches) 
within the same MS run; to determine which analysis method would be most 
appropriate here, I chose one of the three runs from each replicate to analyze both 
ways (sums and PD medians). For comparison purposes, I narrowed the dataset 
down to peptides meeting 30% CV across A, B, and C. In Figure 41, note that the 
PD method consistently produced more reproducibly quantified peptides than the 
summation method. For this reason, the following data are PD-derived ratios from 
a MudPIT scored analysis of the three runs from each replicate set. 
To examine data quality, I counted the number of blank values for each tag 
(represented as the corresponding mouse) across all PSMs. It was clear that 
replicate A had a significantly higher proportion of blanks for tags representing 
reversibly oxidized thiols, while also having the fewest total PSMs (Figure 42).  
 131 
 
 
Figure 41. Comparing two types of TMT quantitation analysis: PD ratios vs Sums 
generated from raw intensities. 
Represented are the number of high confident peptides with TMT quantification at ≤30% 
CV for n=3 (analytical replicates), all derived from one MS run. PD-ratios consistently 
produced more reproducibly quantified peptides. 
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Figure 42. Comparing numbers of blank values for TMT reporter ions that 
represented the 6 different samples: Glrx Tg, WT, and KO reversible oxidation (N) 
and total available thiols (T). 
 A, B, and C are analytical replicates. Left axis: Blank values for each TMT tag are 
represented as a percentage of total peptides (peptide spectrum match or PSM) with a 
nonzero value for at least one tag. Right axis: Line graph indicating total number of PSMs 
for each analytical replicate. Replicate A contained the fewest total PSMs and the highest 
number of blanks for tags representing reversibly oxidized thiols in all three genotypes. 
This is likely due a mistake in preparation: one extra C18 desalting step was completed 
on A. 
 
This was likely due to a mistake in sample handling, where replicate A was 
desalted twice with C18 columns rather than once. Due to high losses compared 
to replicates B and C, the latter two were analyzed hereforth. Also, this would be 
the most appropriate comparison to make for method evaluation, as only 
duplicates were available for computation of CVs in the Cat Tg dataset. 
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In our article discussing the Cat Tg mice, we only compared animals fed chow diet 
and limited the data to those with a CV of ≤35% for combined biological and 
technical variability (Yao et al., 2015). To allow for in-depth examination of the 
protocols, I reanalyzed the Cat Tg dataset with the same parameters used for the 
new Glrx data, and focused only on technical replicates—which were available for 
WT mice on chow diet and Cat Tg mice on HFHS diet. Data quality and richness 
was evaluated using a frequency histogram displaying the range of CVs (%) for all 
peptides quantified (Figures 43 & 44). There were significant increases in the 
number of quantifiable peptides from the Glrx cohort for all ratios (total available 
thiols, reversibly oxidized thiols, and percent oxidation), except for the lowest CV 
interval (≤5%) of total available thiols (Figure 43 A). Generally, the optimized 
protocol more than doubled the number of peptides that could be reliably 
quantified. 
As a review, the global pattern of log2-transformed fold-change for Cat Tg 
compared to WT mice indicated a slight right-ward shift in total available thiols, 
while reversible and percent oxidation of thiols were diminished (Figure 15). Due 
to the increase in total thiols, we surmised that Cat Tg was preventing irreversible 
oxidation possibly occuring in 8 months old WT mice. Furthermore,  
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Figure 43. CV (%) range for analytical replicates of ratios comparing Glrx and Cat Tg 
cohorts to their respective WT. 
Ratios: (A) total available thiols (“Totals”) and (B) reversibly oxidized thiols 
(“Reversibles”). Except for in the lowest %CV bracket (≤10%), the new protocol delivered 
more reproducibly quantified ratios calculated from total available thiols tags. 
Reproducible measurements of reversibly oxidized thiols increased dramatically with the 
new protocol. 
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Figure 44. CV (%) range from analytical replicates of percent oxidation (OX) for (A) 
WT and (B) genetically modified (GM) mice from Glrx and Cat Tg cohorts. 
After eliminating most of the biological variation (comparing only chow-fed WT mice) the 
new protocol still enabled quantification (≤30% CV) of more peptides. More peptides were 
reliably quantified in the Glrx cohorts processed with the new protocol than in the Cat Tg 
cohort processed with the old protocol. However, some of the increased variation could 
be biological, as Cat Tg mice should have less reversible oxidation and require greater 
sensitivity than afforded in a global discovery experiment. 
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it would make sense that with a dramatic increase in an enzyme that detoxifies 
H2O2, there should be less reversible oxidation of thiols. In the cases of Glrx KO 
and Tg compared to WT there was an opposite trend. Total avaialble thiols were 
mostly centered around zero, with a slight leftward skew—indicating a potential 
increase in irreversible oxidation (Figure 45 C). Additionally, both reversible and 
percent oxidation increased (Figures 45 A & B); while this might be expected for 
mice lacking Glrx to remove glutathione adducts, it is perplexing that the Glrx Tg 
also showed an increase. If Glrx is overexpressed, logically there should be fewer 
glutathione adducts on proteins in those mice. The proteomics experiment was 
undertaken after mice were already 9 months old. I hypothesize that glrx may play 
different roles at early and later stages of aging. In earlier stages, when antioxidant 
systems are running optimally and oxidants are in check, glrx may maintain 
cysteines in the thiolate form. If there were substantial decreases in total available 
thiols as the mice aged (here they are middleaged), it could indicate that the 
overexpressed Glrx was removing protective adducts and allowing thiols to 
become irreversibly oxidized. But this was not the case here. Possibly, at later 
stages when dysregulation and ROS fluxes increase, overexpressed Glrx could be 
pushed to catalyze the opposite reaction, adding glrx adducts to proteins. 
Alternatively, expression of the Glrx transgene may  
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Figure 45. Log2 transformed fold-change between Glrx KO or Tg and WT. 
Ratios were from TMT tags representing (A) percent oxidation, (B) reversibly oxidized 
thiols, or (C) total available thiols. Both Glrx KO and Tg were more reversibly oxidized 
(percent oxidation and reversible only) than WT. While the majority of total available 
thiols were not different between Glrx KO or Tg and WT, there was a slight decrease in 
GM mice. This could indicate an increase in irreversible oxidation. 
 
simply decrease as mice age. In the following chapter, I discuss the metabolic 
phenotype of these mice. Briefly, neither cohort was protected from HFHS-diet-
induced sequelae, potentially validating the lack of opposing molecular 
landscapes.  
A key difference between catalase and Glrx overexpression is that the former 
detoxifies endpoint ROS, keeping levels low even in aging or under HFHS diet. 
The latter directly affects protein adducts without regard for the surrounding 
environment. This can leave thiols exposed to detrimental conditions. In addition 
to examining age-dependancy of reversible protein-oxidation levels, some clarity 
might be afforded by measurements of GSH/GSSG ratios. Because Glrx (1) is in the 
cytosol, it would be helpful to measure the cytosol and mitochondrial (matrix) 
separately. If the GSH/GSSG ratio is lower in the Glrx Tg, it could meet the Km of 
the reverse reaction. 
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Prior to the experiments in this report, we did not know how Glrx Tg mice would 
respond to HFHS diet. Our lab has previously shown that a Glrx KO cohort fed 
chow diet eventually experiences fatty liver and glucose intolerance and HFHS 
simply exacerbates this already poor outcome. As indicated above, from logic, we 
would have expected the opposite effect at the molecular and phenotypic levels in 
the Glrx Tg. Initially, our hypothesis for looking at site-specific protein cysteine 
oxidation in chow-fed Glrx KO and Tg mice was that sites specifically 
deglutathionylated by Glrx should be increased in the KO and decreased in the 
Tg. This would reveal glutathione sites without requiring an in vitro Glrx-
mediated reduction step in our switch technique. Just as the cases discussed in the 
background suggest, it was not that simple.  
Next, I compared percent oxidation of peptides that overlapped between Glrx Tg 
and KO animals. After preparing a ratio of Tg over KO and converting the decimal 
values to negative fold change, positive values indicated greater percent oxidation 
in Tg, while negative fold changes indicated increased percent oxidation in KO. A 
1.5-fold change cutoff was applied to indicate significance then each group was 
analyzed separately with Ingenuity Pathway Analysis (Qiagen, Redwood City, 
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Ca) (Table 10). This revealed some interesting trends as well as expected 
associations.  
In line with previous studies in our lab that showed Glrx KO mice on chow diet 
eventually experience NAFLD, “Hepatic Fibrosis” was indicated as the top 
canonical pathway for proteins with thiols more oxidized in KO mice (Figure 46). 
Upon closer inspection, the proteins that matched to this pathway were cardiac-
derived; it is likely that similar factors cause fibrosis in both organs. Central 
“nodes” from a signaling network mapped from the top hits with negative fold-
change (green, KO %OX > Tg %OX) included TNF, FGF2 (Fibroblast Growth 
Factor 2), BGN (Biglycan), and others, all of which are involved in inflammation 
and structural changes (Figure 47). BGN was directly oxidized in the dataset, while 
the others were central to a variety of oxidized proteins branching out from the 
“nodes”. BGN has been indicated in atherogenesis, vascular damage, as well as in 
promoting collagen fibril formation (Mandraffino et al., 2014; Westermann et al., 
2008). FGF2 has been shown to promote cardiac hypertrophy and fibrosis (Itoh 
and Ohta, 2013). As I will discuss in the following chapter, Glrx KO mice fed HFHS 
diet experience significantly, albiet slightly, worsened cardiac  
 141 
 
  
 F
ig
u
re
 4
6.
 T
o
p
 I
P
A
 c
an
o
n
ic
al
 p
at
h
w
ay
s 
m
at
ch
in
g
 t
o
 p
ro
te
in
s 
w
it
h
 t
h
io
ls
 t
h
at
 w
er
e 
1.
3
-f
o
ld
 m
o
re
 o
xi
d
iz
ed
 (
ca
lc
u
la
te
d
 
u
si
n
g
 %
o
xi
d
at
io
n
) 
in
 G
lr
x 
K
O
 t
h
an
 T
g
. 
 
 142 
 
 
 
Figure 47. Ingenuity Pathway Analysis (IPA, Qiagen) top network for proteins with at 
least one thiol in KO that was 1.3-fold more oxidized (%OX) than in Tg. 
The extent of the difference in oxidation is indicated by increasing green intensity. Central 
“nodes” in the network included TNF, FGF2 (Fibroblast Growth Factor 2), BGN 
(Biglycan), and others, all of which are involved in inflammation and structural changes. 
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hypertrophy compared to WT mice on HFHS diet. These results potentially point 
to important players in cardiac remodeling that are either controlled via cysteine 
oxidation or whose oxidation could serve as a biomarker. 
Interestingly, proteins containing peptides that were more oxidized in Glrx Tg 
animals (positive, red) primarily contribute to growth and metabolism, with TCA 
cycle, “Mitochondrial Dysfunction”, and Oxidative Phosphorylation as the top 
three matching canonical pathways (Figure 48). Largely, oxidized proteins were 
enzymes involved in energy production, while the network nodes were classic 
survival and growth regulators. These included P38 MAPK (mitogen activated 
protein kinase; cardiac hypertrophy (Streicher et al., 2010)), ERK (extracellular 
signal-related kinase), AKT (Protein kinase B; glucose metabolism, coronary 
angiogenesis, hypertrophy (Chaanine and Hajjar, 2011)), PI3K (phosphoinositide 
3-kinase), and Pkc (protein kinase C) (Figure 49). Finding many mitochondrial 
enzymes more oxidized in Tg than KO animals might suggest that overexpressed 
Glrx (1), which exists only in the cytosol, plays a role in modulating the oxidative 
environment of the matrix by manipulating GSH/GSSG ratios. While the two pools 
are separate, this could be a point of cross talk between the two compartments via 
GSH transporters. The matrix must  
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Figure 49. IPA (Qiagen) top network for proteins with at least one thiol in Tg that was 
1.3-fold more oxidized (%OX) than in KO. 
The extent of the difference in oxidation is indicated by increasing red intensity. Central 
“nodes” in the network were classic survival and growth regulators, including P38 
MAPK, ERK, AKT, PI3K, and Pkc. Proteins directly oxidized were primarily enzymes 
involved in energy production. 
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derive all of its GSH from the cytosol; if overexpressed Glrx is acting as a sink for 
free GSH, this could potentially deprive mitochondria of the high levels of GSH 
required to help maintain the matrix in a more reduced state than the cytosol. 
Again, unintended consequences of overexpressed Glrx may account for the fact 
that we saw similar levels of oxidized proteins in the Tg as we did in the KO. 
Alternatively, Glrx may be reducing glutathione adducts in the cytosol as 
expected, but because this glutaredoxin isoform (1) cannot reach the mitochondrial 
matrix, that is where we see most of the increased protein oxidation in Tg mice. In 
summation, results from IPA helped reveal that the primary pathways affected 
under the two geotypes were largely distinct. 
Metabolic and Cardiac phenotypes of HFHS-fed Glrx Tg and KO mouse 
cohorts 
We have demonstrated previously that WT mice fed HFHS diet experience the 
classic hallmarks of metabolic syndrome in humans, including increased body 
weight, decreased glucose tolerance, increased plasma cholesterol and 
triglycerides (TG), and eventually diastolic dysfunction. To examine the role of 
protein glutathione adducts in development of metabolic CVD, Glrx Tg and KO 
mice were assessed for their response to HFHS-feeding. A variety of experiments 
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done in Glrx Tg and KO mice on other backgrounds and with different assaults 
complicated our hypotheses. As discussed in the introduction, a Glrx KO mouse 
was protected from cardiovascular hypertrophy induced by high dose Ang II 
infusion (mimicking high blood pressure and cardiovascular remodeling). 
However, when a Glrx Tg mouse was crossed with a mouse model for heart failure 
(Gαq overexpression), it too was protected from cardiovascular remodeling. 
Although it was unclear what we should expect in these mice, investigating their 
response to a more relevant stimulus like diet would provide insight into the 
oxidative changes underlying metabolic remodeling. 
The mice were started on HFHS or calorie-matched control diet at 3-4 months. 
With help from Fuzhong Qin in the Colucci lab, heart function was evaluated 
using echocardiography after 5-6 months on diet. Before final body weight 
measurement, sacrifice, and tissue harvest at approximately 9 months, a fasting 
glucose tolerance test was performed. Finally, plasma from blood captured via 
cardiac puncture was frozen and eventually used to test TG and cholesterol levels. 
Glrx Tg mice experienced a significant increase in body weight with HFHS feeding 
(2-way ANOVA: 0.0176; Figure 50 A), however, post-hoc tests indicated that diet 
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equally affected both Tg and WT. Their glucose tolerance was decreased (2-way 
ANOVA 0.0293, Figure 50 B) and interestingly, both HFHS-fed animals  
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Figure 50. Select metabolic parameters of Glrx Tg cohort. 
(A) Body weight was significantly increased by HFHS-diet in both genotypes. (B) Glucose 
tolerance testing indicated that, following a bolus of glucose, mice recovered more slowly 
if they had been fed HFHS-diet, with Glrx Tg experiencing the highest peak blood glucose 
level. (C) Although 2-way ANOVA was insignificant, Bonferroni post-test indicated that 
plasma cholesterol levels were highly significantly increased by HFHS-diet. 
 
peak glucose occurred later, at around 60 minutes rather than 30. Diet similarly 
significantly increased cholesterol levels in WT and Tg mice (2- way ANOVA: ns, 
posttest: diet p=0.0059; Figure 50 C), while TG measurements were inconclusive. 
Glrx Tg certainly did not protect these mice from diet-induced metabolic 
syndrome; rather, it appears the effect was not significantly different from WT.  
Conversely, multiple trends indicated that Glrx KO mice fared worse than WT 
mice when fed HFHS diet. Body weight and TGs were significantly increased by 
diet, yet similarly affected both WT and KO mice (Figure 51 A & B). However, a 
strong trend toward increased heart ventricle weight (normalized to tibia length) 
was observed (2-way ANOVA 0.0684, Figure 51 C). This measure of cardiac 
hypertrophy was further validated with F. Qin’s m-mode and tissue Doppler echo 
results. Just as in humans, these mice exhibited preserved ejection fraction (normal 
systolic function; Figure 52 A-C, LV-D, -S, -FS), while wall thickness (TWTh) 
increased and early diastolic filling velocity (E’) decreased (Figure 52 D & C). 
When comparing all four groups (including chow diet), a 2-way ANOVA for 
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TWTh was insignificant, but a posthoc test suggested wall thickness was strongly 
increased by diet in both genotypes (p<0.0001). Means were extremely 
significantly different according to a one-way ANOVA (0.0003), while a Mann-
Whitney (non-parametric) test between just HFHS-fed KO and WT mice indicated 
a strong trend toward increased thickness in KO (p=0.0547). Decrease in E’ is 
considered the earliest marker of diastolic dysfunction in humans (Nagueh et al., 
2009) and this change was nearly significant in the KO cohort on diet (2-way 
ANOVA p=0.0855). When examining the differing contribution of genotype and 
diet to this overall trend toward variance, the p value for genotype was 0.0607 and 
diet <0.0001. 
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Figure 51. Select metabolic parameters of Glrx KO cohort. 
(A) HFHS-diet significantly increased body weight and (B) plasma TGs in both WT and 
Glrx KO. (C) Cardiac hypertrophy, measured by ventricle weight to tibia length, was 
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increased by HFHS-diet (p=0.0099), potentially even moreso in KO (2-way ANOVA 
interaction p=0.0684). 
 
 
Figure 52. Echocardiography of Chow- and HFHS-fed Glrx WT and KO mice, courtesy 
of Fuzhong Qin. 
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(A-C) LV end-systolic dimension (LV-S), diastolic dimension (LV-D), and fractional 
shortening (FS%) were not different among the groups. (D) Total wall thickness (TWTh) 
2-way ANOVA post-tests, 1-way ANOVA, and non-parametric T-test (for HFHS-diet 
groups only) were significantly different or showed a strong trend. (E) Left ventricular 
relaxation measured with tissue Doppler imaging (E’ filling velocity) was decreased in 
HFHS-fed mice, and to a greater degree in Glrx KO mice (trend). 
 
Future directions and current collaborations 
Given a trend toward worsened cardiac outcome in the Glrx KO animals, they 
would be an ideal model for further proteomic studies applying the protocols 
developed in this work. Not only are the Glrx KO mice easier to study with 
proteomics—due to increased oxidation helping separate signal from noise for 
more measurements—the comparison to WT would also highlight the oxidatively 
modified cysteines strongly associated with remodeling. The boost in sensitivity 
and accuracy afforded by the methods optimized here will be critical to this effort, 
as the phenotype is mild. The role of targets identified in these experiments can 
then be further interrogated using in vivo mutation studies employing adeno-
associated virus constructs in the Glrx KO mice. 
While the hearts from these cohorts are perfused and ready for proteomics, other 
organs are already furthering a variety of investigations in the labs of our 
collaborators. Working with fresh red blood cells from these Glrx KO mice, we 
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were able to aid Christine Winterbourn and her lab in establishing Glrx as an 
alternative recycling mechanism for peroxiredoxin 2 in erythrocytes (Peskin et al., 
2016). Sending the brains of HFHS-fed Glrx Tg mice to the Mieyal lab in Ohio 
facilitated discovery of a novel, detrimental role for Glrx in promoting 
neuroinflammation and dopaminergic loss associated with Parkinson’s disease 
(Gorelenkova Miller et al., 2016). This finding revises conventional knowledge in 
the field. Finally, preliminary studies using the lungs from both cohorts are 
helping the Janssen-Heininger lab dissect mechanisms that underlie development 
of obese asthma. 
Concluding Remarks 
In this work, I have devised and optimized a method for quantifying percent 
reversible oxidation of protein cysteines in a mouse model for MetS-induced CVD. 
In my first application of the method, I identified that enzymes involved in energy 
production were the primary targets of changing oxidation in HFHS-diet fed 
C57B6J mice. In a collaborative effort to validate findings from those preliminary 
results, we determined that two cysteines in Complex II of the ETC progress from 
reversibly to irreversibly oxidized over the course of chronic HFHS feeding. 
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Importantly, these modifications decreased ATP output by cardiac mitochondria, 
potentially depriving the heart of the energy it needs for calcium handling and 
constant contraction/relaxation. While investigating the effect of H2O2-induced 
oxidation, colleagues and I determined that the switch technique and proteomics 
methods needed refinement. I was able to significantly improve reproducibility 
and minimize artefactual oxidation, creating an optimized protocol that can be 
applied to questions investigating the role of redox signaling in a variety of tissues. 
These methods combined the power of systems biology with cysteine site 
specificity, enabling discovery of central pathways and important targets involved 
in pathological remodeling. Finally, in an effort to assess the particular 
contribution of protein-glutathione adducts to diet-induced CVD, I characterized 
the Glrx Tg and KO mouse response to HFHS feeding. Glrx KO animals exhibited 
increased protein-oxidation compared to WT, which could be attributed to 
preserved GSH modifications. HFHS diet resulted in worsened outcomes for Glrx 
KO mice, paving the way for further investigations into how GSH-mediated 
signaling propels MetS into CVD. 
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APPENDIX 
Table 9 Thiol oxidation in heart proteins from mice fed a Western diet. 
(Behring et al., 2014) 
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Table 10 Thiol oxidation in heart proteins from Glrx Tg and KO mice. 
Cysteines represented here are those with ≥1.5-fold difference in % oxidation between 
Glrx Tg and KO mice. 
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